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The cholesterol metabolites known as oxysterols play an important role in 
maintaining cell homeostasis. They play vital roles in inflammation, cell growth, 
cell signaling, immunity, oxidative stress and aging. Following the discovery that 
the most abundant oxysterol, 27-hydroxycholesterol (27-OHC) is a Selective 
Estrogen Receptor Modulator (SERM), it has been implicated in hormonal 
cancers such as breast and uterine cancer. 27-OHC is a ligand of estrogen 
receptors (ER), a nuclear hormone receptor involved in cell growth and 
proliferation. The downstream events followed by 27-OHC-induced ER activation 
in the context of breast cancer is unknown. Also, the role of 27-OHC in prostate 
cancer is ill-defined given the involvement of ER in prostate cancer (PCa) and 
benign prostatic hyperplasia (BPH). Our studies delineate for the first time a 
potential cellular mechanism of action of 27-OHC in the context of ER+ breast 
cancer, whereby 27-OHC induced ER activation in ER+ MCF7 cells increases 
cell proliferation via perturbing the p53-MDM2 axis. We demonstrate that 27-
OHC, through ER, exacerbated p53 inactivation via MDM2 resulting in an 
increase in cell proliferation in ER+ breast cancer cells. Next, we address the 
possibility of 27-OHC exacerbating prostate cancer cell proliferation. In the 
context of BPH and PCa, we show that 27-OHC not only increased cell 
proliferation in tumorigenic cell lines, LNCaP and PC3 but also in the non-
tumorigenic cells, RWPE-1. We further demonstrate that 27-OHC- induced cell 
xiii 
 
proliferation in prostate cells is specifically through ERβ. Given the tissue 
dependent selective ER modulation of 27-OHC, our novel findings suggest that 
27-OHC activates ER signaling in the prostate. Altogether, our findings elucidate 
and establish the novel role and cellular mechanism of action of the oxysterol 27-
OHC in the context of breast and prostate cancer. In the interest of discovering 
new therapeutic avenues for breast and prostate cancers, our work may aid in 
the development of novel therapies that could mitigate/halt/alleviate the 





Oxysterols: The Arcane Derivatives of Cholesterol 
Cholesterol is a critical component of the cell membranes of the cells. It 
helps to preserve the fluidity of the cell membranes which is vital to maintain cell 
homeostasis (Róg and Vattulainen 2014). Two thirds of cholesterol in our bodies 
are synthesized de novo, while the rest is acquired through dietary 
sources(Dietschy 1984).  
Cholesterol is synthesized de novo in the following steps; first, acetyl CoA 
is converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). Second, HMGCoA 
is converted to mevalonate by the rate limiting enzyme, 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGCoA reductase). Third, mevalonate is 
converted to an isoprene based compound, isopentenyl pyrophosphate (IPP) 
which is later transformed into squalene. Lastly, following a series of reactions, 
squalene is converted to cholesterol which eventually becomes vital precursor of 
vitamin D, all steroids and bile salts (Singh et al. 2013; Di Ciaula et al. 2014; King 
2016) (Fig.1).  
Cholesterol regulation is important to cell survival. Cholesterol can be 
regulated by the rate limiting HMGCoA reductase enzyme, regulation of the
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amount of intracellular free cholesterol by sterol O-acyl transferases (SOAT1 and 
SOAT2) and regulation of plasma cholesterol levels via Low Density Lipoprotein 
(LDL) receptor facilitated uptake and High Density Lipoprotein(HDL) reverse 
transport (Goedeke and Fernández-Hernando 2012; van der Wulp et al. 2013; 
King 2016). Close observation and regulation of the plasma cholesterol (including 
HDL and LDL fractions) is the most common physiological indicator that 
clinicians use to diagnose and curb hypercholesterolemia in patients (Grundy 




Figure 1: A diagram of the cholesterol biosynthetic pathway. Acetyl CoA 
converted to HMG CoA which, through a series of reactions leads to the 
synthesis of cholesterol which is a precursor to bile salts, vitamin D and steroids 
(reproduced from King 2016). 
In addition to being a precursor to steroid hormones (Gabitova et al. 
2013), bile acid and vitamin D (Berg et al. 2002), cholesterol is a precursor (as 
cholesterol continues to exist even after oxidations to oxysterols) to a family of 
steroid-like compounds called oxysterols. Oxysterols are oxidized cholesterol 
metabolites which have various signaling consequences in inflammation, 
immunity, cellular signaling, lipid metabolism, development and apoptosis (Brown 
and Jessup 1999; Björkhem 2002; Javitt 2008; Sato 2010; Vesa M Olkkonen et 
al. 2012; Björkhem 2013). 
Oxysterols are a 27-carbon compound with a cholesterol like backbone 
containing either an epoxide or ketone or an additional hydroxyl group in the 
sterol center and/or a hydroxyl group in the side chain (Vurusaner et al. 2016 




Figure 2: Structure of cholesterol and its main oxidation sites in red. (reproduced 
from Vurusaner et al. 2016 Mar) 
Oxysterols are synthesized by autoxidation or by a specific 
monooxygenase secondary to enzymatic/non-enzymatic lipid peroxidation. There 
are several oxysterols generated via cholesterols including but not limited to: 7-
hydroepoxycholesterol, 7α-hydroxycholesterol, 7β-hydroxycholesterol, 7-
oxocholesterol, cholesterol 5α,6α-epoxide, cholesterol-5β,6β-epoxide, 4β-
hydroxycholesterol, cholestane-3β,5α,6β-triol, 27-hydroxycholesterol, 25-
hydroxycholesterol, 24S-hydroxycholesterol, 24,25-epoxycholesterol and so forth 
(Björkhem and Diczfalusy 2002). 
The most abundant oxysterol in the brain is 24S-hydroxycholesterol (24S-
OHC) while 27 hydroxycholesterol (27-OHC) is predominantly found in the 
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periphery (Burkard et al. 2007a; Ramirez et al. 2008; Rantham Prabhakara et al. 
2008; Hirayama et al. 2009; Björkhem et al. 2013; Bandaru and Haughey 2014). 
These two oxysterol have been implicated in numerous diseases, particularly in 
neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease 
(Rantham Prabhakara et al. 2008; Dasari et al. 2010; Marwarha et al. 2011; 
Bandaru and Haughey 2014; Marwarha and Ghribi 2015). 
 
Figure 3: A schematic diagram depicting the biosynthesis of the major oxysterols. 
The enzymatically derived products are indicated in green, cholesterol 
metabolites derived from autoxidation with red, and yields derived from shunt 




In this dissertation, I will focus on the role of the most abundant oxysterol 
in the plasma, 27-OHC, in breast and prostate cancers. 27-OHC has been 
implicated to play significant role in inflammation (Umetani et al. 2014), 
Alzheimer’s disease (Marwarha and Ghribi 2015), Parkinson’s disease (Björkhem 
et al. 2013) and atherosclerosis (Umetani et al. 2007a; Karuna et al. 2011). In 
this disquisition, I will introduce my findings to establish the newly characterized 
deleterious role of 27-OHC in hormone-dependent cancers of the breast and 
prostate.     
Breast Cancer 
Breast cancer is the most common cancer amongst American women, 
with one in every eight women developing this disease (Gonzalez-Angulo et al. 
2007). The etiology of breast cancer appear to be multi-factorial, including 
environmental agents and genetic susceptibilities playing a role in the 
pathophysiology of this disease.  
ER alpha and its hormonal ligand, estradiol play a significant role in the 
development and progression of ER-positive breast cancers (Doisneau-Sixou et 
al. 2003; Arpino et al. 2005; Bailey et al. 2012; Coates et al. 2012; Renoir et al. 
2012) which account for 70% of all breast cancers (Harrell et al. 2006). There are 
multiple risk factors associated with breast cancer, including 
hypercholesterolemia (Printz 2014), obesity (James et al. 2015), Type 2 diabetes 
(Crujeiras et al. 2013) and hormone dyshomeostases (Jankowitz and Davidson 
2013; Bodicoat et al. 2014). 
7 
 
 Breast cancer develops when the normal breast epithelium transforms 
into atypical breast hyperplasia, ductal carcinoma in situ, invasive ductal 
carcinoma and eventually a metastatic cancer (Fig. 4). Molecular events leading 
to the progression at each step of this debilitating disease are yet to be 
determined, however it is hypothesized that steroidal hormones and their 
receptors play a vital role in this disease (Rivenbark et al. 2013). 
 
Figure 4: A schematic diagram displaying the canonical progression of breast 
cancer pathology (reproduced from Gómez-Suaga et al. 2014) 
Breast cancers are classified based on patterns of gene expression in the 
corresponding subtypes. Molecular subtypes have been developed primarily 
based on five major biomarkers found in the breast tissue: ER, progesterone 
receptor (PR), human epidermal growth factor receptor 2 (HER2), cytokeratin 5/6 
and human epidermal growth factor receptor 1 (HER1). ER+ breast cancers are 
8 
 
sub-classified as luminal A or Luminal B. Luminal A subtype expresses 
ER+/PR+/HER2- , while luminal B expresses ER+/PR+/HER2+. Likewise, non-
luminal or ER- breast cancers, are subclassified as either HER2+ i.e ER-/PR-
/HER2+ or HER2-, ER-/PR-/HER2-, which is also known as triple negative breast 
cancer (TNBC) (Fig. 5). Additionally, basal like breast cancers can be identified 
using the remaining markers: cytokeratin 5/6 and HER1. This method of 
molecular classification of breast cancer subtypes does not encompass all 
clinically diagnosed breast cancer cases, however it comprises of most of the 
breast cancers diagnosed and potentially determines the hormone dependence 
(or lack thereof) of the breast cancer tumor based on its receptor status 
(Rivenbark et al. 2013). Other types of breast cancers include HER2 enriched 
and Claudin-low breast cancers (Prat et al. 2011; Cancer Genome Atlas Network 
2012). Patients with ER+ breast cancers are usually treated with anti-estrogens 
such as tamoxifen, while those with ER- breast cancers are treated with 
alternative approaches based on HER2 receptor status;  for instance, 
trastuzumab (anti-HER2 drug) to target HER2+ non-luminal breast cancers (Ali 





Figure 5: A diagram depicting the classification of all breast cancers based on 
available immunohistochemistry marker profiles (reproduced from Blows et al. 
2010). 
ER signaling pathways can be affected by the abundance of estrogens 
and estrogen like molecules in the body, diet and/or the environment. 
Uncontrolled ER activation can also occur due to mutations and epigenetic 
events leading to the development of atypical breast hyperplasia subsequently 
ER+ breast cancer (Kun et al. 2003; Renoir et al. 2012; Rivenbark et al. 2013).  
Currently, for ER+ breast cancers, hormone therapy is the frontline 
therapeutic avenue utilized by clinicians to combat ER+ breast cancer tumor 
growth (Baum et al. 2002a; McKeage et al. 2004; Renoir et al. 2012). There are 2 
distinct ways by which hormone therapy works: by directly blocking estrogens 
and estrogen like molecules using competitive ER antagonists and by reducing 
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the bioavailability of estrogens through inhibiting their biosynthesis via aromatase 
inhibitors. While both strategies are effective, there is a concern of ER+ breast 
cancer cells being ‘desensitized’ and becoming less dependent on estrogens for 
tumor growth. It is well known that patients often develop resistance to hormone 
therapy during the course of their treatment and require a combination of 
alternative therapies (including radiotherapy) to effectively curb ER+ tumor 
growth and/or metastasis (Hasson et al. 2013; Hart et al. 2015).  
The cholesterol metabolite 27-OHC, binds to estrogen receptor (ER) and 
elicits ER signaling. 27-OHC is characterized as a Selective Estrogen Receptor 
Modulator (SERM) and provokes ER activation in the breast, several lines of 
evidence have suggested its deleterious role in ER+ breast cancer progression 
(Cruz, Torres, María Eugenia Ramírez, et al. 2010; Umetani and Shaul 2011; 
Nelson et al. 2013; Wu et al. 2013; Raza et al. 2015). 27-OHC not only increased 
the proliferation of breast cancer cells in vitro (Cruz, Torres, María Eugenia 
Ramírez, et al. 2010; Nelson et al. 2013; Singh et al. 2013; Wu et al. 2013; Raza 
et al. 2015), but also increased tumor growth  in CYP7B1−/−/MMTV-PyMT mice, 
with high levels of 27-OHC. The increased tumor growth was rescued in these 
mice by the administration of an ER- specific inhibitor, fulvestrant(Nelson et al. 
2013). Also, 27-OHC content in ER+ breast cancer tissue is higher when 
compared to normal breast tissue from breast cancer patients (Wu et al. 2013). 
These studies underline the importance of 27-OHC induced ER activation in ER+ 
breast cancer tumor growth. 
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In this document, we will discuss the role of 27-OHC in ER+ breast cancer 
cell proliferation and delineate a potential cellular mechanism of action of 27-
OHC and its impact on the p53-MDM2 axis in the context of ER+ breast cancers. 
Prostate Cancer 
Every year almost 230,000 men are diagnosed with prostate cancer. 
Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) predominantly 
occur in older men (Chodak 2006; Dhingra and Bhagwat 2011). The etiology of 
PCa and BPH appear to be multifactorial with age as the most commonly 
identified major risk factor (Gann 2002; Chokkalingam et al. 2003; William G. 
Nelson, M.D., Ph.D., Angelo M. De Marzo, M.D., Ph.D., and William B. Isaacs 
2003; Bostwick et al. 2004). Other risk factors that contribute to PCa and BPH 
include oxidative stress (Khandrika et al. 2009), hypercholesterolemia (Moon et 
al. 2015) and obesity (Burton et al. 2010).  
PCa which affects one in every six men in the US, is an ailment that leads 
to the enlargement of the prostate due to the presence of cancer cells that could 
metastasize to the bone or the lymph nodes (Sato et al. 1997). On the other 
hand, BPH is the enlargement of the prostate due to hyperplasia of the prostatic 
stroma and/or glandular elements. In PCa, the prostate enlargement is not only 
due to the hyperplasia of stromal cells but also the prostatic epithelial cells. 
However, PCa and BPH, both have symptoms that overlap each other making it 
difficult during diagnosis, especially during early stages of PCa (Chokkalingam et 
al. 2003; Shukla et al. 2016).  
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PCa and BPH share risk factors associated with them (Fig. 6). However, 
the relationship between the two is yet to be elucidated. There are two schools of 
thought, with one claiming PCa and BPH as two separate disorders while the 
other believes that BPH is a condition that precedes and eventually leads to PCa 
development (Ørsted and Bojesen 2013). According to the latest and only 
systematic review to date, which examined 16 case-control studies and 10 cohort 
studies, patients with BPH have ~2.9 fold increased incidence of PCa (Dai et al. 
2016). However, there is currently little to no evidence to suggest that BPH 
always progresses to PCa. While both conditions have shared risk factors, some 
risk factors may favor the transformation of BPH to PCa. For instance, 
inflammation is a risk factor for BPH and PCa, however some studies have 
established that BPH tissues with inflammatory infiltrates were more likely to 
advance to PCa than those without inflammation (Higgins and Thompson 2002; 








Figure 6: A pictorial diagram depicting the difference and shared risks between 
BPH and PCa (reproduced from Ørsted and Bojesen 2013).  
Urologists currently distinguish between BPH and PCa using a biomarker 
such as prostate specific antigen (PSA) and histological examination of prostatic 
tissue. PSA levels are much higher in PCa patients versus BPH patients and 
presence of pre-cancerous lesions in prostatic biopsies indicate PCa while the 
absence of it indicates BPH (Geybels et al. 2013; Shukla et al. 2016) (Fig. 7). 
More non-invasive biomarkers are being identified to better distinguish between 
PCa and BPH: novel biomarkers include β-2 microglobulin(β2M), pepsinogen 3, 




Figure 7:  Histopathology of biopsy specimen. Prostate biopsy specimen: (A–C) 
Adenocarcinoma (magnification, ×100), (D) benign prostate (glandular) 
hyperplasia and (E) non-lesion area. (hematoxylin and eosin stain; scale bars, 
100 μm) (reproduced from Miyazawa et al. 2014) 
 PCa is an ailment that morphs as it goes through 4 stages of 
development. The first 2 stages (T1 and T2) include a confined tumor in the 
prostate. At stage 3 (T3), the tumor invades the seminal vesicles and at stage 4  
(T4) the tumor metastasizes to adjacent structures such as the lymph nodes and 






Figure 8: Stages of PCa and possible treatment regimens at various stages of 




Cholesterol involvement in prostate cancer has been suspected for over a 
century when it was found to accumulate in prostate cancer tissues (White 1909). 
More recent studies also demonstrate a positive correlation between high plasma 
cholesterol and high-grade prostate cancers (Mondul et al. 2010). Diets rich in 
cholesterol have also been shown to induce metastasis in prostate cancer(Moon 
et al. 2015). However, statins, a class of drugs which competitively inhibit 3-
hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCoA reductase), a key 
enzyme in cholesterol synthesis pathway, is unable to rescue or predict 
prognosis of patients with PCa (Geybels et al. 2013; Algotar et al. 2014; Kantor 
et al. 2015).  
The impact of cholesterol in prostate cancer may be through its oxidized 
metabolite, 27-OHC. Levels of 27-OHC increase with age, oxidative stress, and 
hypercholesterolemia (Hirayama et al. 2009; Dasari et al. 2010; Prasanthi et al. 
2011; Nelson et al. 2013). These factors are all suspected to increase the risk of 
developing PCa and BPH. In this thesis, I will also discuss the potential role of 









ROLE OF 27-HYDROXYCHOLESTEROL IN BREAST CANCER 
27-hydroxycholesterol Regulates p53 activity and Increases Cell 
Proliferation via MDM2 in Breast Cancer Cells. 
Abstract 
Estrogen is synthesized from cholesterol and high cholesterol levels are 
suggested to be associated with increased risk of estrogen receptor(ER)-positive 
breast cancer. The cholesterol metabolite 27-hydroxycholesterol (27-OHC) was 
recently identified as a selective estrogen receptor modulator (SERM) and has 
been shown to impact breast cancer progression. However, the mechanisms by 
which 27-OHC may contribute to breast cancer are not all known. We determined 
the extent to which 27-OHC regulates cell proliferation in MCF7 ER positive 
breast cancer cell line involving the tumor suppressor protein p53. We found that 
treatment of MCF7 cells with 27-OHC reduced p53 transcriptional activity. 
Conversely, treatment of the ER negative MDA MB 231 cells with 27-OHC 
induced no change in p53 activity. Exposure of MCF7 cells to 27-OHC was 
associated with increased protein levels of the E3 ubiquitin protein ligase MDM2 
and decreased levels of p53. Moreover, 27-OHC also enhanced physical 
interaction between p53 and MDM2. Furthermore, 27-OHC induced proliferation 
was attenuated using either the p53 activator Tenovin-1 or
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the MDM2 inhibitor Nutlin-3 and Mdm2 siRNA. Taken together, our results 
indicate that 27-OHC may contribute to ER positive breast cancer progression by 
disrupting constitutive p53 signaling in an MDM2 dependent manner. 
Introduction 
Breast cancer is the most common cancer amongst American women, 
with one in every eight women developing this disease (Gonzalez-Angulo et al. 
2007). The causes of breast cancer are multi-factorial, including environmental 
agents and genetic susceptibilities. ER alpha and its agonists, estradiol (and 
estradiol-like compounds), play a significant role in the progression of ER-
positive breast cancer forms. Several therapeutic strategies have been 
developed against ER, however a significant number of ER-positive breast 
carcinoma patients experience drug resistance (Baum et al. 2002b; Buzdar 2004; 
Franco et al. 2004). 
27-OHC has been characterized as an endogenous ligand for ER 
(Umetani and Shaul 2011; Nelson et al. 2013; Wu et al. 2013). 27-OHC is an 
oxysterol formed from cholesterol through the enzyme CYP27A1. This oxysterol 
is the most abundant cholesterol metabolite in plasma, and also accumulates in 
macrophages. In vitro, 27-OHC elicits a signaling response via ER at 
concentrations as low as 0.1µM (Wu et al. 2013). In the plasma of healthy human 
subjects, 27-OHC is found at concentrations of 0.2-0.6µM, and these 
concentrations can increase dramatically under conditions such as 
hypercholesterolemia (Duane and Javitt 1999). Thus, fluctuations in 27-OHC 
may modulate ER and potentially contribute to the pathogenesis of ER+ breast 
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cancers. While it has been established that 27-OHC is an endogenous selective 
ER modulator (SERM) and that it exacerbates breast cancer pathophysiology 
(DuSell et al. 2008; Cruz, Torres, María Eugenia Ramírez, et al. 2010; Nelson et 
al. 2013), its role in molecular events following ER activation in the context of 
breast cancer pathogenesis is not fully understood. 
The tumor suppressor protein, p53 plays an important role in apoptosis, 
cell cycle and senescence. Under normal conditions, wild type p53 is in “stand 
by” mode. Under genotoxic stress, p53 is activated to prevent anomalous cell 
proliferation and neoplastic development. Hence, p53 has been extensively 
studied as an anticancer target and as a cancer prognostic tool to diagnose and 
treat several types of cancers (Pharoah et al. 1999; van der Burg et al. 2001; 
Miller et al. 2005; Coates et al. 2012; Walerych et al. 2012; Ahn et al. 2013; Khoo 
et al. 2014). Levels of p53 are regulated by the E3 ubiquitin ligase, Mouse 
Double Minute 2 protein (MDM2). MDM2 tags p53 to undergo ubiquitination and 
subsequently proteasomal degradation (Moll and Petrenko 2003; Manfredi 2010; 
Dolfi et al. 2014). In this report, we determined the effects of 27-OHC on cell 
proliferation in the context of p53 and MDM2 regulation. We found that 27-OHC 
via ER inhibits p53 transcriptional activity in an MDM2 dependent manner, 





27-OHC was purchased from Santa Cruz Biotechnologies (Santa Cruz, CA), the 
p53 activator, tenovin-1 from Tocris Bioscience (Ellisville, MO), Nutlin-3 and 
Fulvestrant from Cayman Chemicals (Ann Arbor, MI), the reporter constructs 
encoding p53 response elements conjugated to the firefly luciferase gene from 
SA Biosciences (Frederick, MD) and β-estradiol from Sigma-Aldrich (St. Louis, 
MO). All cell culture reagents, with the exception of fetal bovine serum (Atlanta 
Biologicals, Lawrenceville, GA) were from Invitrogen (Carlsbad, CA). Human 
MCF7 and MDA MB 231 cell lines were purchased from ATCC (Manassas, VA). 
Cell Culture 
The human ER-positive breast cancer cells MCF7 and ER-negative breast 
cancer cells MDA MB 231 were grown in phenol red free DMEM/F12 medium 
containing 10% charcoal dextran stripped fetal bovine serum (FBS) and 1% 
antibiotic/antimycotic mix. Cells were maintained at 37°C in a saturated humidity 
atmosphere containing 95% air and 5% CO2. 
Cell Proliferation Assays 
Proliferation assays were conducted on black 96 well plates using CyQUANT 
Direct Cell Proliferation Assay purchased from Invitrogen (Carlsbad, CA), which 
quantifies cell number using DNA content and membrane integrity. Cells were 
processed for proliferation as per manufacturer’s protocol and read using Spectra 
MAX GEMINI EM (Molecular Devices).  
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Dual Luciferase Assays 
Dual Luciferase Reporter Assay System (Promega; Madison, WI) was used to 
determine the effect of 27-OHC on p53 activity. MCF7 and MDA-MB-231cells 
were incubated for 18 hours with transfection ready p53 response element 
conjugated with firefly luciferase construct and constitutively expressing Renilla 
Luciferase construct (SA biosciences; Valencia, CA) using Lipofectamine 2000  
(Invitrogen; Carlsbad, CA) as per the manufacturer’s recommendations. Firefly 
luciferase readings were normalized against constitutive Renilla luciferase 
readings.  
Western Blot Analysis 
Treated MCF7 cells were washed with PBS, trypsinized and centrifuged at 5000 
g. The pellets were washed with PBS and homogenized in M-PER tissue protein 
extraction reagent (Thermo Scientific; Waltham, MA) supplemented with 
protease and phosphatase inhibitors. Denatured proteins (5 µg) were separated 
in 10% or 12.5% SDS-PAGE gels, transferred to a PVDF membrane (Millipore; 
Billerica, MA) and incubated with antibodies to p53 (1:1000, Thermo Scientific; 
Waltham, MA) or MDM2 (1:1000, Santa Cruz; Dallas, TX). β-actin was used as a 
gel loading control for the whole cell homogenates. The blots were developed 
with enhanced chemiluminescence (ECL Clarity kit, Bio-Rad; Hercules, CA). 
Bands were visualized on a PVDF membrane and analyzed by LabWorks 4.5 
software on a UVP Bioimaging System (Upland, CA). Quantification of results 
was performed by densitometry and the results analyzed as total integrated 




Co-Immunoprecipitation (Co-IP) in cell homogenates was performed for p53 and 
MDM2 using “Catch and Release” immunoprecipitation kit (Millipore; Billerica, 
MA) according to the manufacturer's protocol. Briefly, 3×106 MCF7 cells were 
homogenized in Mammalian Protein Extraction Reagent (MPER) supplemented 
with protease and phosphatase inhibitors (Thermo Scientific; Waltham, MA). The 
homogenates containing the equivalent to 500μg of total protein content were 
incubated with 2μg of p53 mouse antibody (1:1000; Thermo Scientific; Waltham, 
MA) or 2μg of MDM2 mouse antibody (1:1000; Santa Cruz; Dallas, TX) overnight 
in the spin columns followed by elution. Eluate from p53 antibody precipitated 
protein-antibody complex (5µL) was resolved on a SDS-PAGE gel transferre onto 
a polyvinylidene difluoride (PVDF) membrane (BioRad; Hercules, CA) and 
incubated with MDM2 antibody followed by development with enhanced 
chemiluminescence ECL clarity (Bio-Rad; Hercules, CA). Analogously, eluate 
from anti-MDM2 antibody precipitated protein-antibody complex (5µL) was 
resolved on a SDS-PAGE gel transferred onto a PVDF membrane and incubated 
with p53 antibody followed by development with enhanced chemiluminescence 
ECL clarity. Bands were visualized on a PVDF membrane and analyzed by 
LabWorks 4.5 software on a UVP Bioimaging System. 
Double Immunofluorescence Staining 
Coverslip seeded cells were rinsed with PBS and fixed in cold acetone, blocked 
with 10% normal goat serum and incubated overnight at 4˚C with p53 antibody 
(anti-rabbit) and MDM2 antibody (anti-mouse). p53 was conjugated to Texas Red 
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and MDM2 to Alexa Fluor 488. All coverslips were washed and mounted with 
Vectashield containing DAPI and visualized with a Zeiss LSM 510 META 
confocal system coupled to a Zeiss Axiophot 200 inverted epifluorescence 
microscope (Carl Zeiss Microscopy; Dublin, CA). Quantification of percent 
overlap was determined using MetaMorph Microscopy Automation and Image 
Analysis Software (Molecular Devices). 
Small Interfering RNA 
The cells were transfected with MDM2 siRNA using Lipofectamine 2000 
(Invitrogen; Carlsbad, CA) and incubated for 48 hours, followed by their 
respective treatments. Control (scrambled) siRNA were obtained from Santa 
Cruz Biotechnologies (sc-37007; Dallas, TX) . The siRNA to MDM2 sense and 
antisense strands were: GCUUCGGAACAAGAGACCC and 
GGGUCUCUUGUUCCGAAGC (Santa Cruz; Dallas, TX).  
Statistical Analysis 
All the assays were carried out in triplicates. Groups were compared using 
unpaired t-tests and One-Way Analysis of Variance (One-Way ANOVA) followed 
by Tukey’s post-hoc test to correct multiple comparisons. Statistical analyses 
were performed with GraphPad Prism software 4.01. Quantitative data for all 
experimental analyses are presented as mean values ± S.E.M with unit value 
assigned to control and the magnitude of differences among the samples being 





27-OHC Increases Proliferation in ER+ Breast Cancer Cells  
27-OHC has been reported to be a novel SERM and an agent that can promote 
ER+ breast cancer growth (DuSell et al. 2008; Cruz, Torres, María E. Ramírez, et 
al. 2010; Nelson et al. 2013; Wu et al. 2013). As cell proliferation is considered a 
hallmark of tumor growth and cancer progression (Gao et al. 2005), we 
measured proliferation with and without 27-OHC treatment in ER-positive MCF7 
and ER-negative MDA MB 231 cell lines. Treatment of MCF7 with 0.1 or 1µM 27-
OHC increased cell proliferation by about 80% compared to treatment with 
vehicle (Fig. 9a). Treatment with estradiol of MCF7 cells also increased 
proliferation in a magnitude comparable to that of 27-OHC. On the other hand, 
the ER-negative cells MDA MB 231 did not exhibit significant proliferation when 
treated with 27-OHC (Fig. 9b). These result are in accordance with the recent 
discovery that 27-OHC binds to ER and exacerbates ER-positive breast cancers 




Figure. 9: 27-OHC induces proliferation in breast cancer cell lines. (a)  
Proliferation assay in the MCF7 cells shows an increase in proliferation 48h after 
treatment with 0.1 or 1μM of 27-OHC and 2nM Estradiol (E2) compared to 
treatment with vehicle. (b) In contrast to MCF7 cells, the MDA MB 231 cells 
exhibit no change in proliferation in the presence of 27-OHC either at 0.1 or 1μM 
concentration for 48h. Data is expressed as Mean ± S.E.M. ***p<0.001 versus 
vehicle 
27-OHC Reduces Transcriptional Activity of p53  
p53 is often mutated in breast cancers, thus implicating disruption of this gene in 
breast cancer progression. Moreover, p53 is a promising target in breast cancers 
(Sørlie et al. 2001; Walerych et al. 2012). MCF7 is one of the few breast cancer 
cells which has wild type p53, most ER+ breast cancer cell lines have mutated 
p53 (Okumura et al. 2002; Wasielewski et al. 2006). We used the MCF7 cell line 
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which is a commonly used cell model for breast cancer therapeutics studies 
(Comşa et al. 2015; Lee et al. 2015). Published work suggests that 27-OHC 
stimulates cell proliferation in breast cancer cells but not in normal breast 
epithelial cells (Cruz, Torres, María E. Ramírez, et al. 2010; Nelson et al. 2013; 
Wu et al. 2013). Since MCF7 cells express wild type p53, it is vital to examine the 
impact of 27-OHC on p53 activity (Okumura et al. 2002; Zheng et al. 2004; 
Wasielewski et al. 2006; Lim et al. 2009). Subsequently, we transfected cells with 
a luciferase reporter linked to a p53 receptor element and treated with 27-OHC.  
Treatment of MCF7 cells with 0.1 or 1µM 27-OHC significantly decreased p53-
driven transcription by ~25% compared to incubation with vehicle (Fig. 10a). 
Interestingly, treatment with estradiol did not induce changes in p53 activity 
compared to vehicle (Fig. 10a). In the ER-negative MDA MB 231 cells, 27-OHC, 
either at 0.1 or 1µM, exerted no detectable effect on p53 activity (Fig. 10b). To 
test whether the 27-OHC effect on p53 mediated transcription was via ER, we 
used fulvestrant, an ER inhibitor. We found that co-treatment with fulvestrant 
attenuated the 27-OHC induced p53 inactivation (Fig. 10c). This result suggests 






Figure 10: 27-OHC reduces p53 activation. (a) Luciferase reporter assay in 
MCF7 cells showed lower p53 activity in the presence of 0.1μM 27-OHC, 1μM 
27-OHC, or 2nM Estradiol (E2) for 24h. (b) No change in p53 activity was 
detected with the luciferase reporter assay in the ER-negative MDA MB 231 cells 
treated with 0.1μM or 1μM 27-OHC for 24h. (c) Luciferase reporter assay in 
MCF7 cells demonstated that fulvestrant, an ER inhibitor, attenuates 27-OHC 
induced p53 inactivity when treated with 1µM 27-OHC and/or 5µM of fulvestrant. 
Data is expressed as Mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 versus 
vehicle.##p<0.01 versus 27-OHC only. RLU=Relative Luciferase Units 
27-OHC Regulates p53 and MDM2 Expression  
Regulation of p53 degradation is important to maintain its activity. MDM2 plays a 
critical role in regulating p53 levels by enhancing p53 degradation. MDM2 
catalyzes p53 degradation by flagging it for destruction. In contrast, during DNA 
damage MDM2 undergoes self-ubiquitination and downregulates its own 
expression, which leads to the upregulation of the DNA damage response 
through p53 (Moll and Petrenko 2003; Manfredi 2010). MDM2 is overexpressed 
in human cancers where it causes the disruption of p53 signaling and potentially 
other oncogenic pathways (Moll and Petrenko 2003; Manfredi 2010). We 
determined the effect of 27-OHC on p53 and MDM2 expression levels using 
western blot analyses. We found that treatment of cells with 27-OHC decreased 
p53 expression levels by ~50% and increased MDM2 expression levels by ~28% 
compared to vehicle (Fig. 11a-c). This result suggests that 27-OHC 






Figure 11: 27-OHC reduces p53 and increases MDM2 levels. (a) Representative 
western blot and densitometric analysis of MCF7 cells showing a substantial 
decrease in p53 levels (b) and a significant increase in MDM2 levels (c) following 
treatment with 1µM of 27-OHC for 24h. Data is expressed as Mean ± S.E.M. 
*p<0.05 versus vehicle 
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27-OHC Enhances p53 and MDM2 Dimerization 
The relationship between p53 and MDM2 has been widely studied. MDM2 is 
known to bind to p53 and shuttle it to the cytoplasm for degradation (Alarcon-
Vargas 2002; Moll and Petrenko 2003).  To determine whether 27-OHC 
enhances the interaction between MDM2 and p53, we performed a co-
immunoprecipitation assay. We found that treatment with 27-OHC increased 
MDM2 and p53 binding. When MDM2 was blotted against p53 immuno-
precipitated lysate or when p53 was blotted against MDM2 immuno- precipitated 
lysate, an increase in staining for the other protein was observed (Fig. 12a). We 
also used double immunofluorescence staining to observe p53-MDM2 co-
localization. Subsequently, we found that 27-OHC treatment, caused a significant 
increase in overlap of labelled p53 and MDM2 at the nuclear envelope (Fig. 







Figure 12: 27-OHC promotes p53-MDM2 interaction in MCF7 cells. (a) 
Representative non-denatured western blots for p53 IP blotted against MDM2  
and MDM2 IP blotted against p53 demonstrating an increase in p53-MDM2 
binding in of MCF7 cells treated for 24h as follows: lane 1 Rabbit Serum 
(negative control); lane 2: lysate only; lane 3, 4: vehicle only; lane 5,6: 1µM 27-
OHC.  (b) Representative confocal microscopy images showing increased 
intensity of MDM2 staining (green) and reduced intensity of p53 staining (red) 
following treatment of MCF7 cells with1µM 27-OHC. Arrows indicate co-
localization of p53 and MDM2 in MCF7 cells treated with 1µM 27-OHC for 24h. 
Bar, 10µm. (c) Representative graph showing increased percent of overlap 
between MDM2 and p53 in the confocal images. Data is expressed as Mean ± 
S.E.M. *p<0.05 versus vehicle 
27-OHC Increased Proliferation via MDM2 Mediated p53 Inactivity  
To determine whether 27-OHC promotes cell proliferation via p53 inactivation; 
we treated cells with the p53 activator, Tenovin-1 (Lain et al. 2008). We found 
that Tenovin-1 significantly increased p53 transcriptional activity (Fig 13a) and 
inhibited 27-OHC-induced proliferation (Fig. 13b). This suggests that p53 
inactivation is necessary for 27-OHC induced cell proliferation. Given that 27-
OHC treatment increased MDM2 levels, enhanced MDM2-p53 binding and 
decreased p53 levels (Fig. 11&12), we tested whether if 27-OHC-induced cell 
proliferation was due to MDM2 dependent p53 degradation. We treated cells with 
the MDM2-p53 interaction inhibitor, Nutlin-3 (Park et al. 2013). We found that 
Nutlin-3 blocked 27-OHC-induced cell proliferation comparable to that of basal 
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levels (Fig. 13c). This result suggests that MDM2-p53 binding is required for 27-
OHC induced cell proliferation. To investigate if MDM2 expression is specifically 
necessary for 27-OHC induced cell proliferation, we knocked down MDM2 
expression using siRNA. Inhibition of MDM2 blocked 27-OHC induced cell 
proliferation (Fig. 13d,e). This data strongly suggests that 27-OHC requires 




Figure 13: 27-OHC induces proliferation via MDM2-mediated p53 inactivation. (a) 
Luciferase reporter assay demonstrates an increase in p53 activity in MCF7 in 
the presence of 10μM Tenovin-1 for 48h. (b) Cell proliferation assay 
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demonstrates that 27-OHC-induced proliferation is attenuated by Tenovin-1 in 
MCF7 cells. Cells were treated vehicle, 1μM 27-OHC, 10μM Tenovin-1, or 1μM 
27-OHC + 10μM Tenovin-1 for 48h. (c) In MCF7 cells, 1μM 27-OHC-induced 
proliferation is also attenuated by the MDM2-p53 interaction inhibitor Nutlin-3. 
Cells were treated with vehicle, 1μM 27-OHC, 5μM Nutlin-3, or 1μM 27-OHC + 
5μM Nutlin-3 for 48h. (d) Representative blot demonstrates MDM2 knock down 
efficiency in MCF7. (e) 1μM 27-OHC-induced proliferation is also attenuated by 
MDM2 siRNA. Cells were incubated with respective treatments for 48h. Data is 
expressed as Mean ± S.E.M. versus vehicle. Data is expressed as Mean ± 
S.E.M. *p<0.05, **p<0.01, ***p<0.001 versus vehicle, and ### p<0.001 versus 27-
OHC only. RLU=Relative Luciferase Units 
Discussion 
The goal of this study was to elucidate cellular mechanisms involved in 
27-OHC-induced proliferation in breast cancer cells. Our results demonstrate that 
27-OHC decrease p53 activity and protein levels, which results in increased cell 
proliferation. Our study also shows that 27-OHC increases MDM2 levels and 
enhances the interaction between p53 and MDM2. We further show that 27-
OHC-induced proliferation is dependent on MDM2-mediated p53 degradation. 
Our results are the first showing that 27-OHC acting through ER, exacerbates 
breast cancer cell proliferation via the p53-MDM2 axis. 
P53 is a highly regulated protein in the cell and has a short half-life 
(Giaccia and Kastan 1998). Loss of p53 function and/or perturbations in its 
signaling pathways via mutations plays an important role in several cancers 
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(Hanahan and Weinberg 2000; Sherr and McCormick 2002; SHERR 2004). p53 
plays an important role in “guarding the genome” from genotoxic stress and 
regulates apoptosis, cell cycle, senescence and metabolism. Lack of functional 
p53 leads to abnormalities in cell cycle and apoptosis, which may lead to cancer 
progression. Approximately, 23% of breast cancers exhibit a p53 mutation and 
loss of p53 function via mutation remains one of the main molecular 
characteristics of breast carcinomas, while more spontaneous cancers such as 
ovarian, intestinal, and lung cancers have higher incidences of p53 mutations 
(Walerych et al. 2012; Yu et al. 2014 Apr 23). In this report, we show that the 
cholesterol oxidation metabolite 27-OHC dysregulates p53 expression and 
function. 
We report that 27-OHC, a SERM, inhibited wild type p53 activity, while 
interestingly, estradiol, a standard and endogenous ligand for ER had no effect 
on p53 activity. This demonstrates that 27-OHC may contribute to ER-positive 
breast cancer progression via different mechanisms compared to known 
estrogens.  To verify that 27-OHC exerted it effects via ER, we treated cells with 
fulvestrant, an ER inhibitor, concomitantly with 27-OHC and found that it blocked 
the p53 transcriptional inactivation effects of 27-OHC. This demonstrates that 
while 27-OHC and estradiol activate the same receptor (ER), the downstream 
events appear to be distinct. Regulation of estrogen levels in humans has been 
extensively studied and is a primary target for therapy using interventions such 
as aromatase inhibitors and ovarian ablation (Gonzalez-Angulo et al. 2007). 
Although hormone therapy is relatively effective, such therapy is challenged by 
37 
 
endocrine resistance and recurrence of breast cancers. Hormone therapy is 
designed to specifically reduce estrogen levels (Hasson et al. 2013; Jankowitz 
and Davidson 2013). The recent discovery that 27-OHC also activates ER and 
promotes ER-positive breast cancer progression, may explain why hormone 
therapy may not be as effective as expected. Furthermore, a recent study by 
Nelson and colleagues demonstrated that the gene expression profile in MCF7 
breast cancer cells grown in the presence of 27-OHC was remarkably different 
relative to estradiol-treated MCF7 cells, with 788 unique genes in the 27-OHC 
profile that are different from the estradiol profile of 8141 genes (Nelson et al. 
2013). In the above mentioned study, 27-OHC and estradiol regulated 1511 
shared genes (Nelson et al. 2013). Understanding the role of 27-OHC in ER-
positive breast cancer may reveal novel molecular mechanisms that play a role in 
breast cancer progression, resistance and recurrence of breast cancers.  
There is a positive correlation between cholesterol and 27-OHC levels in 
humans. Patients with hypercholesterolemia have higher levels of 27-OHC and 
thus may be at a greater risk for developing ER-positive breast cancer (Nelson et 
al. 2013). 27-OHC is synthesized from cholesterol through hydroxylation by a 
cytochrome P-450 enzyme, sterol 27 hydroxylase (CYP27A1), localized in the 
inner mitochondrial membrane of the liver. 27-OHC is a substrate for bile acid 
synthesis, and when bile acid levels are adequate, excess levels of 27-OHC are 
catabolized by CYP7B1 (Fu et al. 2001; Ma et al. 2014 May 1).  In support of 
hypercholesterolemia as a risk factor for developing breast cancers, the use of 
cholesterol lowering agents, such as HMG-CoA reductase inhibitors (statins),  
38 
 
has been associated with better prognosis and breast cancer survival rates 
(Ahern et al. 2011). Furthermore, Cruz et al showed that in ER-positive 
mammary tumor cells, simvastatin blocked 27-OHC induced cell proliferation 
(Cruz, Torres, María E. Ramírez, et al. 2010). 
Our results add further insights into the potential molecular mechanisms 
by which 27-OHC influences cancer cell progression. We show that 27-OHC 
increases levels of the E3 ubiquitin ligase MDM2 and its interaction with p53. 
MDM2 is known to regulate p53 activity by flagging it for ubiquitination and 
proteasomal degradation (Alarcon-Vargas 2002). Since DNA damage is a potent 
activator of p53, prior to DNA damage MDM2 binds to both p53 and ribosomal 
protein RPL26 resulting in ubiquitination and proteasomal degradation. Upon 
DNA damage, p53 and MDM2 undergo posttranslational modifications, inhibiting 
their interaction and subsequently activating p53 activity (Moll and Petrenko 
2003; Khoo et al. 2014). In the presence of 27-OHC, MDM2 and p53 interaction 
is enhanced, resulting in p53 inactivation and degradation. It is suggested that 
MDM2 by itself may be an oncogene (Momand 1998; Wang et al. 1999). MDM2 
is overexpressed in various cancers including sarcoma, leukemia, breast 
cancers, melanoma, and glioblastoma (Jones et al. 1998; Momand 1998).  
We also demonstrate that 27-OHC-induced cell proliferation in the ER-
positive breast cancer MCF7 cells is dependent on the inactivation of p53. 
Treatment with Tenovin-1, a potent p53 activator, attenuated 27-OHC-induced 
cell proliferation. This supports the notion that 27-OHC induced p53 inactivation 
promotes breast cancer cell proliferation. Since p53 can undergo inactivation and 
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degradation through multiple mechanisms (Moll and Petrenko 2003; Kruse and 
Gu 2009; Tsvetkov et al. 2010), it was vital to test the role of MDM2 specifically in 
27-OHC induced p53 inactivation that led to cell proliferation. To verify whether 
p53 inactivation is MDM2-dependent, we treated cells with Nutlin-3, an MDM2-
p53 interaction inhibitor (Miyachi et al. 2009; Poyurovsky et al. 2010). We found 
that Nutlin-3 prevents MDM2 mediated and 27-OHC-induced degradation of p53. 
We also found that upon knocking down MDM2, 27-OHC induced cell 
proliferation was attenuated, suggesting that inactivation of p53 is MDM2 
dependent. This data indicates that 27-OHC exacerbates ER-positive breast 
cancer progression by inactivating and degrading p53 via MDM2.  
Although the prognostic value of p53 in ER-positive breast cancers is 
controversial, we propose that in the presence of excess 27-OHC, p53 function is 
compromised via MDM2, causing an exacerbation of ER-positive breast cancer 
progression. Subsequently, activation of p53 has been considered to be an 
important therapeutic target in tumorigenesis and cancer progression. A number 
of small molecules have been developed to activate wild type p53 and reactivate 
mutant p53. Interestingly, both DNA based and dendritic cell delivered p53 
vaccines have been developed to activate and upregulate p53 (van der Burg et 
al. 2001; Speetjens et al. 2009). In addition, gene therapy has been used against 
breast carcinomas (Obermiller et al. 2000; Sasaki et al. 2001; Song and Boyce 
2001; Rejeeth and Kannan 2014 May 4). Recently, Rejeeth et al. (2014) used 
silica nanoparticle supplemented with transferrin to administer p53 to MCF-7 and 




Figure 14: Proposed mechanism of action of 27-OHC in ER+ breast cancer. 27-
OHC activates ER, which upregulates MDM2 and mediates p53 inactivation and 
degradation resulting in increased in cell proliferation. Thus, exacerbating ER+ 
breast cancer progression. Activation is denoted by arrows; inhibition is indicated 
by bars 
In summary, we demonstrate that 27-OHC exacerbates ER-positive MCF7 
cancer cell proliferation by disrupting p53 activity. We propose that 27-OHC 
activates ER, an effect that leads to activation of MDM2 and subsequent 
inactivation of p53. Fulvestrant, an ER specific antagonist, blocks 27-OHC 
activation of ER, resulting in disinhibition of Mdm2-mediated p53 transcriptional 
activity. It has been shown that ER activation enhances MDM2 expression and 
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that fulvestrant attenuates MDM2 upgregulation by inhibiting ER (Dolfi et al. 
2014). Since ER upregulates MDM2, which in turn inactivates p53, we asked if 
fulvestrant would inhibit MDM2-mediated p53 inactivation. Indeed, when we 
measured p53 activity, we found that fulvestrant inhibited 27-OHC-induced 
Mdm2-mediated p53 inactivation (Fig.10). Our data indicates that 27-OHC acting 
through ER can disrupt the p53 response. We suggest that individuals with high 
levels of 27-OHC may have an increased risk of developing ER-positive breast 
cancers via loss of constitutive p53 activity. We also demonstrate that 27-OHC 
enhances MDM2-p53 interaction resulting in loss of p53 expression and activity. 
Such results strongly suggest an MDM2 involvement in the 27-OHC-induced p53 
inactivity and subsequent cell proliferation (Fig. 14). Our findings provide a novel 
molecular mechanism for 27-OHC that may contribute in the pathophysiology of 
ER-positive breast cancers. Understanding the MDM2-p53 interplay in the 
presence of 27-OHC may reveal innovative therapeutic avenues that can inhibit 





ROLE OF 27-HYDROXYCHOLESTEROL IN PROSTATIC HYPERPLASIA 
27-hydroxycholesterol Stimulates Cell Proliferation and Resistance to 
Docetaxel-induced Apoptosis in Prostate Epithelial Cells 
Abstract 
Although the causes of prostate cancer (PCa) and benign prostatic hyperplasia 
(BPH) are not known, the role of oxidative stress, aging, and diet are suspected 
to increase the incidence of prostate complications. The cholesterol oxidation 
derivative (oxysterol) 27-hydroxycholesterol (27-OHC) is the most prevalent 
cholesterol metabolite in the blood.  As aging, oxidative stress, and 
hypercholesterolemia are associated with increased risk of PCa and BPH, and 
because 27-OHC levels also increased with age, hypercholesterolemia and 
oxidative stress, determining the role of 27-OHC in the progression of PCa and 
BPH is warranted. In this study, we determined the effect of 27-OHC in human 
prostate epithelial cells RWPE-1. We found that 27-OHC stimulates proliferation 
and increases androgen receptor (AR) transcriptional activity. 27-OHC also 
increased PSA expression and enhanced AR binding to the androgen response 
element compared to controls. Silencing AR expression with siRNA markedly 
reduced the 27-OHC-induced proliferation. Furthermore, 27-OHC blocked 
docetaxel-induced apoptosis.  Altogether, our results suggest that 27-OHC may  
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play an important role in PCa and BPH progression by promoting proliferation 
and suppressing apoptosis. 
Introduction 
Prostate health is an area of growing concern. Over 14% of men will 
develop prostate cancer (PCa) and greater than 70% of men will develop benign 
prostatic hyperplasia (BPH) by the age of 70 (Guess et al. 1990; Delongchamps 
et al. 2006). The etiologies of PCa and BPH are unknown but environmental 
factors including diet are suggested to play a role in the progression of these 
pathologies. Aging, genetic susceptibility, obesity, low physical activity, 
androgens, and inflammatory conditions are all associated with both PCa and 
BPH (Chokkalingam et al. 2003; Ørsted and Bojesen 2013).  
Cholesterol involvement in PCa has been suspected for over a century 
when it was found to accumulate in PCa cells (White 1909). More recent studies  
demonstrated a positive correlation between high plasma cholesterol and high-
grade PCa (Mondul et al. 2010). Moreover, some studies reported a reduction in 
the risk of high-grade PCa (Breau et al. 2010; Papadopoulos et al. 2011) and 
BPH (Lee et al. 2013) with the cholesterol-lowering statins. However, the efficacy 
of lowering cholesterol levels currently is not proven and whether increased 
cholesterol levels are causal factors of PCa and BPH is still unknown.
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Several lines of evidence suggest that cholesterol oxidation products, not 
cholesterol per se, may increase the risk of PCa and BPH risk. 27-OHC is the 
main oxysterol in the circulation, and its levels can be increased by aging, 
oxidative stress, and hypercholesterolemia (Hirayama et al. 2009; Nelson et al. 
2013), factors that are all suspected to increase the risk for PCa and BPH. 
Evidence suggests that 27-OHC can be deleterious as it can act as a SERM 
(DuSell et al. 2008; Umetani and Shaul 2011) and a liver X receptor (LXR) ligand 
(Fu et al. 2001). Both ER and LXR are involved in steroid signaling pathways and 
influence inflammation, cell proliferation, and many other metabolic processes. 
However, the extent to which 27-OHC also regulates androgen receptors (AR) 
which play a central role in the pathogenesis of BPH and PCa is yet to be 
determined. In this study we determined the effects of 27-OHC on cell 
proliferation and the role of AR in 27-OHC induced cell proliferation.  
We found that 27-OHC increases cell proliferation and AR transcriptional 
activity. We also demonstrate that 27-OHC enhances AR binding to the Prostate 
Specific Antigen (PSA) promoter and increases PSA expression. To investigate 
whether AR is required in 27-OHC-induced cell proliferation, we silenced AR 
gene expression using siRNA and found that 27-OHC induced cell proliferation is 
AR dependent. Additionally, to determine whether 27-OHC contributes to 
apoptosis-resistance, we treated cells with 27-OHC and docetaxel and found that 
27-OHC inhibits the pro apoptotic effects of docetaxel by visualizing nuclear 
fragmentation using TUNEL assay. Overall, our data supports the notion that 27-
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OHC induces cell proliferation in an AR-dependent manner and that 27-OHC 
exhibits anti-apoptotic activities in prostate cells. 
Methods 
Reagents 
27-OHC was purchased from Santa Cruz Biotechnologies (Dallas, TX), docetaxel 
and fulvestrant from Cayman Chemicals (Ann Arbor, MI), β-estradiol from Sigma-
Aldrich (St. Louis, MO) and the reporter constructs encoding androgen receptor 
response elements conjugated to the firefly luciferase gene from SA Biosciences 
(Valencia, CA). All cell culture reagents, with the exception of fetal bovine serum 
(FBS) (Atlanta Biologicals; Flowery Branch, GA) were from Invitrogen. Human 
RWPE-1 cells were purchased from ATCC (Manassas, VA). Concentrations of 
solvent in treatments was less than 0.1%. 
Cell Culture  
Non-tumorigenic human prostate epithelial RWPE-1 cells were maintained in 
Keratinocyte serum free medium (Invitrogen; Carlsbad, CA) supplemented with 
0.05mg/ml BPE and 5ng/ml EGF. Cells were supplemented with 100U/ml 
penicillin, 100μg/ml streptomycin 0.25μg/ml amphotericin (Sigma; St.Louis, MO) 
and cultured at 5% CO2 and 37˚C.  Cells were treated with vehicle (ethanol in 
media), 0.1 μM or 1μM of 27-OHC. Stock solutions of 27-OHC were prepared in 
100% ethanol and stored at -80°C. 27-OHC stock solution was dissolved in 
appropriate volumes of media to prepare the working solutions of 0.1 μM or 1μM. 
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Our study was approved by the Institutional Biosafety Committee at the 
University of North Dakota. 
Cell Proliferation Assays 
To determine the effects of 27-OHC on cell proliferation, we treated cells with 27-
OHC at concentrations that have been shown to promote breast cancer 
progression (Cruz, Torres, María E. Ramírez, et al. 2010; Nelson et al. 2013; Wu 
et al. 2013). Proliferation assays were conducted on black 96 well plates using 
CyQUANT Direct Cell Proliferation Assay (Invitrogen; Carlsbad, CA) which 
quantifies cell number using DNA content and membrane integrity. Cells seeded 
at 5x103 cells/well were treated with vehicle, 0.1 μM or 1μM of 27-OHC and 
incubated for 48 hours. Cells were then stained as per the manufacturer’s 
protocol and read using Spectra MAX GEMINI EM (Molecular Devices; 
Sunnyvale, CA). 
Metabolic Activity Assay  
Cell metabolic activity was quantified by measurement of the reduction of 
MTS to formazan product using CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega; Madison, WI) according to the manufacturer’s 
protocol. The assay of the formation of formazan was performed by measuring 
absorbance change using a microplate reader (Spectromax plus; Molecular 




Dual Luciferase Assays 
Dual luciferase assays were conducted on white 96 well plates using the Dual 
Luciferase Reporter Assay System (Promega; Madison, WI). Cells were 
incubated for 18 hours with transfection ready AR response element conjugated 
with firefly luciferase construct and constitutively expressing Renilla Luciferase 
construct using Lipofectamine 2000 (Invitrogen; Carlsbad, CA) as per the 
manufacturer’s protocol. Following transfection cells were treated with 0 
(vehicle), 0.1 or 1μM 27-OHC for 24 hours. After 24 hours of treatment, cells 
were lysed and measured in Relative Luciferase Units (RLU) as per the 
manufacturer’s protocol. Firefly luciferase readings were normalized against 
constitutive Renilla luciferase readings. 
Chromatin Immunoprecipitation (ChIP) Analysis 
ChIP analysis was performed to evaluate the extent of AR binding to the DNA 
elements in the androgen receptor elements (ARE) regions respectively using 
SimpleChIP™ Enzymatic Chromatin IP kit (Cell Signaling; Beverly, MA). Briefly, 
cells from each treatment group (1×107 cells) were washed with PBS, 
trypsinized, and centrifuged at 5000 g. The pellet containing the cells was further 
washed with PBS and cross-linked using 37% formaldehyde for 15 min followed 
by the addition of glycine solution to cease the cross-linking reaction. The cells 
were washed with 4x volumes of 1x PBS and centrifuged at ~300g for 5 min. The 
pellet was re-suspended and incubated for 10 min in 5 ml of cell lysis buffer 
containing DTT and protease and phosphatase inhibitors. The cross-linked 
chromatin from each sample was apportioned into three equal parts. One third of 
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the cross-linked chromatin was set aside as “input”. One third of the cross-linked 
chromatin from each sample was incubated with 5 µg of AR rabbit antibody 
(Active Motif), while the remaining one third of the cross-linked chromatin from 
each sample was incubated with 5 µg of normal Rabbit IgG to serve as negative 
control. The cross-linked chromatin samples were incubated overnight at 4°C 
with their respective antibodies. The DNA-protein complexes were collected 
using Protein G agarose beads. The samples were incubated with 2 µL of 
Proteinase K for 2 hours at 65°C. The crude DNA extract was eluted and then 
washed several times with wash buffer containing ethanol followed by purification 
with the DNA spin columns. The pure DNA was eluted out of the DNA spin 
columns using DNA elution buffer. The relative abundance of the AR antibody 
precipitated chromatin containing the AR binding site in the ARE region was 
determined by qPCR using an SYBR Green Mastermix kit following the 
manufacturer’s instructions (Invitrogen; Carlsbad, CA). ARE sequence on the 
PSA promoter F: 5′-TCTGCCTTTGTCCCCTAGAT-3′ and R: 5′-
AACCTTCATTCCCCAGGACT-3′ (Horie-Inoue et al. 2004). The amplification 
was performed using Step NE plus PCR Detection System (Invitrogen; Carlsbad, 
CA). The fold enrichment was calculated using the ΔΔCt method which 
normalizes ChIP Ct values of each sample to the % input and background. 
Western Blot Analysis 
Treated cells were washed with PBS, trypsinized, and centrifuged at 5000 g. The 
pellet was washed with PBS and homogenized in M-PER tissue protein 
extraction reagent (Thermo Scientific; Waltham, MA) supplemented with 
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protease and phosphatase inhibitors. Denatured proteins (5 µg) were separated 
in 10% or 12.5% SDS-PAGE gels, transferred to a PVDF membrane (Millipore) 
and incubated with antibodies to PSA (1:1000, Santa Cruz; Dallas,TX), or AR 
(1:1000, Santa Cruz; Dallas, TX). β-actin was used as a gel loading control. The 
blots were developed with enhanced chemiluminescence (ECL Clarity kit, Bio-
Rad). Bands were visualized on a polyvinylidene difluoride membrane and 
analyzed by LabWorks 4.5 software on a UVP Bioimaging System. Quantification 
of results was performed by densitometry and the results analyzed as total 
integrated densitometric values (arbitrary units). 
Small interfering RNA 
The cells were transfected with AR siRNA using Lipofectamine 2000 (Invitrogen; 
Carlsbad, CA) and incubated for 24 hours, followed by their respective 
treatments. siRNA to AR sense and antisense strands were: 5’-
CGGGAAGUUUAGAGAGCUATT-3’,: 5’UAGCUCUCUAAACUUCCCGTG-3’ 
(Hs_AR_5, SA Biosciences; Valencia, CA). 
TUNEL Assay 
The TUNEL assay was performed using DeadEnd Fluorometric TUNEL assay 
(Promega; Valencia, CA) for detection of apoptosis. The TUNEL staining was 
performed according to manufacturer's instructions. Cells were permeabilized 
with Triton-X, washed with PBS, and incubated with terminal deoxynucleotidyl 
transferase, fluorescein-12-dUTP. The fluorescein-12-dUTP labeled DNA was 
then visualized directly by fluorescence microscopy. DAPI was used as counter 
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stain for staining the nucleus. Slides were visualized using DMI 6000 (Leica 
Microsystems; Buffalo Grove, IL). 
Statistical analysis 
The significance of differences were assessed by unpaired t-test and One Way 
Analysis of Variance (One Way ANOVA) followed by Tukey’s post-hoc test. 
Statistical analysis was performed with GraphPad Prism software 4.01. 
Quantitative data for experimental analysis are presented as mean values ± 
S.E.M with unit value assigned to control and the magnitude of differences 
among the samples being expressed relative to the unit value of control.  
Results 
27-OHC increases cell proliferation  
We found that 27-OHC increases proliferation by ~60% at 0.1 µM and 
~40% at 1.0 µM (Fig 15a).  To confirm our results, we performed MTS assay to 
assess the mitochondrial activity of cells. We found that 27-OHC (0.1 and 1 µM) 
also increased the metabolic activity of the cells (Fig 15b). This data suggests 








Figure 15: 27-OHC induces proliferation in prostate cells. Cell proliferation assay 
in RWPE-1 (a) cells demonstrates a significant increase in proliferation in the 
presence of 27-OHC (0.1 and 1μM). MTS assay shows a significant increase in 
cell metabolic activity in the presence of 27-OHC in RWPE-1 (b). Readings were 
recorded 48 hours after treatment with 27-OHC. Data is expressed as Mean ± 
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S.E.M. ***p<0.001 and **p<0.01 versus controls, ###p<0.001 and ##p<0.01 
versus 0.1 μM 27-OHC treatment. 
27-OHC increases AR transcriptional activity 
We treated cells with 27-OHC and measured the transcriptional activity of AR 
using an ARE tagged luciferase reporter. We found that 27-OHC treatment 
significantly increased AR transcriptional activity (Fig. 16).  
 
Figure 16: 27-OHC increases AR transcriptional activity. Luciferase reporter 
assay shows an increase in AR transcriptional activity in the presence of 27-OHC 
(0.1 and 1μM) in RWPE-1 cells. Readings were recorded 24 hours after 





27-OHC increases PSA expression and AR binding to the PSA 
promoter 
Using western blot analyses, we showed elevated levels of PSA in 27-
OHC treated cells. PSA levels significantly increased with 0.1µM and 1.0µM of 
27-OHC (Fig 17 a,b). To determine if the elevated levels of PSA were due to the 
increase in AR transcriptional activity, we performed a ChIP assay to analyze AR 
binding to the androgen receptor element (ARE) on the PSA promoter. We found 
an increase in AR binding to the ARE of the PSA promoter by ~17 fold when 
treated with 0.1µM of 27-OHC and ~11 fold when treated with 1µM of 27-OHC 








Figure 17: 27-OHC increases PSA protein levels via AR. Representative western 
blot (a) and densitometric analysis (b) showing a significant increase in PSA 
protein levels in RWPE-1 cells treated with 27-OHC (0.1 and 1μM) for 48 h. ChIP 
analysis of AR binding to the ARE on the PSA promoter shows an increase in AR 
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binding in the presence of 27-OHC that is higher with 0.1 than 1.0 μM 
concentrations (c). Data is expressed as Mean ± S.E.M. ***p<0.001 versus 
controls, ##p<0.01, and #p<0.05 versus 1µM 27-OHC treatment. 
27-OHC-induced cell proliferation is dependent on AR  
We found that siRNA to AR reduced the protein levels of AR in untreated cells 
(Fig. 18a) and diminished cell proliferation in 27-OHC-treated cells (Fig. 18b). 
This result suggests that 27-OHC-induced cell proliferation involves AR. As 27-
OHC does not directly bind to AR and is an ER modulator (Nelson et al. 2011; 
Umetani and Shaul 2011; Wu et al. 2013), it was important to determine the role 
of ER in prostate cell proliferation. We found that fulvestrant, an ER inhibitor, 
when concomitantly treated with 27-OHC, attenuated 27-OHC induced cell 
proliferation (Fig 18c). This result suggests that ER may function in concert with 





Figure 18: 27-OHC-induced cell proliferation is AR dependent. Western blot 
analysis (a) shows the efficiency of siRNA to AR with protein levels markedly 
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lower in RWPE-1cells treated with siRNA to AR than with scrambled siRNA. Cell 
proliferation assay (b) demonstrates that 27-OHC (0.1µM and 1.0 µM) increases 
cell proliferation and co-treatment with siRNA to AR markedly reduces 
proliferation. The assay was performed following a 24 hour incubation of RWPE-
1cells with the siRNAs on a 96 well plate with their respective treatments. Cell 
proliferation assay (c) demonstrates that 27-OHC induced cell proliferation is 
attenuated when treated with 10µM fulvestrant. Readings were recorded 48 
hours after the treatments. Data is expressed as Mean ± S.E.M. ***p<0.001 
versus vehicle only, ##p<0.01 versus 0.1µM 27-OHC only, ###p<0.001 versus 0.1 
µM or 1µM 27-OHC only treatment. 
27-OHC suppressed docetaxel-induced apoptosis 
Docetaxel is an apoptosis-inducing agent (Mhaidat et al. 2007) and the current 
chemotherapeutic drug of choice for advanced PCa (Petrylak 2000; Petrylak 
2006; Hwang 2012; Kellokumpu-Lehtinen et al. 2013). To determine whether 27-
OHC contributes to chemoresistance, we treated RWPE-1 cells with 27-OHC and 
docetaxel and monitored the number of apoptotic cells by TUNEL assay. We 
found that docetaxel induced apoptosis and 27-OHC (0.1 or 1.0 µM) markedly 
reduced docetaxel-induced apoptosis (Fig. 19). When an apoptotic signal is 
induced, caspase 3 (pro-enzyme) is activated by cleavage to execute apoptosis 
(Porter and Jänicke 1999; McIlwain et al. 2013). We found that docetaxel 
increased levels of both the pro and active caspase-3 (p17). Co-treatment with 
27-OHC opposed the docetaxel-induced increase in pro caspase (Fig. 20 a,b) 





Figure 19: 27-OHC opposes docetaxel-induced apoptosis. Confocal images 
panels (a) and quantitation (b) for TUNEL assay in RWPE-1 cells treated with 27-
OHC and/or docetaxel for 24 h.  Docetaxel (0.1µM) induced a marked increase in 
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the apoptotic cells (Green) and treatment with 27-OHC at both 0.1 and 1.0 µM 






Figure 20. 27-OHC reduces docetaxel-induced caspase-3 cleavage. 
Representative western blot (a) and densitometric analysis (b) showing a 
significant increase in pro-caspase protein levels in RWPE-1 cells when treated 
with 0.1µM docetaxel and concomitant treatment with 27-OHC markedly reduced 
pro-caspase protein levels. Representative western blot (a) and densitometric 
analysis (c) showing a significant increase in cleaved caspase (active, p17) 
protein levels in RWPE-1 cells when treated with 0.1µM docetaxel. Co-treatment 
with 27-OHC markedly reduced cleaved caspase protein levels. Data is 
expressed as Mean ± S.E.M. *p<0.05 versus controls, #p<0.05 versus docetaxel 
only treatment, +p<0.05 and ++p<0.01 versus controls.  
Discussion 
This study was designed to determine the effects of 27-OHC on prostate 
cell proliferation and apoptosis. We also determined the involvement of AR in cell 
proliferation induced by 27-OHC. We demonstrate that 27-OHC increases 
proliferation and activates AR transcriptional activity in the normal prostate cells 
RWPE-1. We further demonstrate that 27-OHC-induced cell proliferation is AR 
dependent. Additionally, we show that 27-OHC opposes apoptotic cell death 
induced by docetaxel. Our data suggests that 27-OHC increases proliferation in 
normal epithelial prostate cells in an AR dependent manner.  
27-OHC, the most abundant cholesterol metabolite in the circulatory 
system, is synthesized by the cytochrome P-450 enzyme, sterol 27 hydroxylase 
(CYP27A1), in the inner mitochondrial membrane of the liver and is metabolized 
by CYP7B1 enzyme (Fu et al. 2001; Ma et al. 2014 May 1). The main source of 
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27-OHC levels in the human body emanates from oxidation of cholesterol. As 
cholesterol levels increase following intake of diets rich in cholesterol or 
overproduction of endogenous cholesterol, production of 27-OHC increases. 
Patients with hypercholesterolemia were reported to have high levels of 27-OHC 
in their blood (Hirayama et al. 2009; Nelson et al. 2011; Nelson et al. 2013). 
Additionally, 27-OHC levels in the plasma have been shown to increase with age 
in males but not in females (Burkard et al. 2007a). Also, males are known to 
have higher basal levels of 27-OHC in plasma than females (Dzeletovic et al. 
1995; Burkard et al. 2007a). 27-OHC is also known to activate or inhibit nuclear 
receptors depending on the target tissue. For instance, 27-OHC inhibits ER 
signaling in the vasculature (Umetani et al. 2007b) and bone (DuSell et al. 2010), 
however it activates ER signaling in breast (Cruz, Torres, María E. Ramírez, et 
al. 2010; Nelson et al. 2013; Wu et al. 2013). 
To the best of our knowledge, there has been no established link between 
27-OHC, PCa and BPH. In this study, we report an increase in cell proliferation in 
prostate cells in the presence of 27-OHC at concentrations below (0.1 µM) or 
above (1.0 µM) the physiological concentrations (Brown and Jessup 1999; 
Marwarha and Ghribi 2015). Total 27-OHC (esterified + non-esterified) is found in 
the human blood plasma ranging from 0.2 to 0.6 µM in a healthy individual 
(Hirayama et al. 2009; Schüle et al. 2010). Also, It has been shown that the 
levels of non-esterified 27-OHC, which is the most biologically active form of 27-
OHC (Meaney et al. 2000; Meaney et al. 2001), is reported to be less than 20% 
of total 27-OHC in the human body (Burkard et al. 2007a; Ramirez et al. 2008; 
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Bandaru and Haughey 2014). In disease conditions, such as cancer and 
neurodegenerative diseases, macrophages migrate to affected areas and 
release excess 27-OHC in the surrounding tissue (Cruz et al. 2012; Nelson et al. 
2013; Bandaru and Haughey 2014). We also found that fulvestrant, an ER 
inhibitor, attenuated 27-OHC induced cell proliferation to the same levels. 
Overall, our data suggests that 27-OHC may play an important role in prostate 
cell proliferation, which may result in the progression of BPH and/or PCa. 
Androgen receptor (AR) plays an important role in prostate growth and 
development. There is a positive relationship between AR transcriptional activity 
and PCa progression (Heinlein and Chang 2004; Lonergan and Tindall 2011). 
Over 80% of PCa patients respond to anti-androgens or androgen deprivation 
therapy that targets and inhibits the AR activity (Heinlein and Chang 2004; Y. 
Chen et al. 2009). Additionally, androgens are also involved in BPH 
pathogenesis via AR (Lu et al. 2012; Izumi et al. 2013). However, the effects of 
cholesterol metabolites including the oxysterol 27-OHC on the AR signaling 
pathway remain to be determined. 
The AR signaling pathway plays a critical role in the development and 
progression of PCa (Heinlein and Chang 2004; Lonergan and Tindall 2011; Izumi 
et al. 2013). AR signaling is chiefly targeted in the context of PCa using androgen 
ablation therapies (Heinlein and Chang 2004; Lonergan and Tindall 2011). As we 
found that AR transcriptional activity was increased with 27-OHC treatment, we 
determined the expression levels of prostate specific antigen (PSA), a well-
known downstream target of AR, increased in these cells (Saxena et al. 2012). 
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PSA is a serine protease, which is produced by prostate epithelial cells and PCa 
cells. It is used as a serum biomarker to monitor PCa progression in patients 
(Kim and Coetzee 2004). Subsequently, we found that levels of PSA were 
increased. Also, using a ChIP assay, we demonstrate that binding of AR to the 
PSA promoter is increased in the presence of 27-OHC. We also show that 27-
OHC-induced proliferation is AR-dependent. When AR gene expression was 
silenced, 27-OHC was unable to increase cell proliferation. As there was no 
additive effect in proliferation when cells were treated simultaneously with 27-
OHC and E2 and because the ER selective inhibitor (Fulvestrant) prevented the 
27-OHC-induced cell proliferation in RWPE-1 cells, we suggest the existence of 
an ER-AR crosstalk in the presence of 27-OHC since we show that the AR 
knockdown also reduces 27-OHC-induced proliferation.  
Since 27-OHC levels increase with age (Burkard et al. 2007a), and 27-
OHC induce AR transcriptional activity, 27-OHC may play a role in castrate-
resistant prostate cancer. However, further studies are needed to evaluate the 
role of 27-OHC in castrate-resistant PCa.  
Apoptosis is an important process that keeps the number of cells dividing 
under tight control (Hipfner and Cohen 2004). To assess the role of 27-OHC in 
regulating apoptosis we utilized a pro-apoptotic drug, docetaxel (Mhaidat et al. 
2007), a current chemotherapeutic drug of choice for advanced PCa (Petrylak 
2006; Kellokumpu-Lehtinen et al. 2013).To further understand whether 27-OHC 
plays a potential role in chemotherapeutic resistance, we treated cells with 
docetaxel and 27-OHC. We found that 27-OHC attenuated the pro-apoptotic 
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effects of docetaxel. While docetaxel is clinically used to battle metastatic PCa 
(McKeage and Keam 2005), it is also pro-apoptotic in non-tumorigenic RWPE-1 
cells (Karanika et al. 2015). To better understand the role of 27-OHC in PCa 
further studies are needed, particularly metastatic PCa models. Our results 
warrant further investigation to understand the anti-apoptotic role of 27-OHC in 
chemotherapeutic resistance to PCa and BPH. 
In summary, we demonstrate that 27-OHC induces an increase in 
proliferation in normal prostatic epithelial cells in an AR dependent manner. We 
also report for the first time, the docetaxel-resistant role of 27-OHC in epithelial 
cells. Our study provides a novel insight into the molecular mechanisms of 27-
OHC and its role in modulating AR signaling pathway that is tightly linked to cell 
proliferation which is associated with PCa and BPH. Further studies are 
warranted to delineate the 27-OHC activated AR signaling pathway which may 








ROLE OF 27-HYDROXYCHOLESTEROL IN PROSTATE CANCER 
The cholesterol metabolite, 27-hydroxycholesterol stimulates cell 
proliferation via ERβ in prostate cancer cells 
Abstract 
For every six men, one will be diagnosed with prostate cancer (PCa) in 
their lifetime. Estrogen receptors (ERs) are known to play a role in prostate 
carcinogenesis. However, it is unclear whether the estrogenic effects are 
mediated by estrogen receptor α (ERα) or estrogen receptor β (ERβ). Although it 
is speculated that ERα is associated with harmful effects on PCa, the role of ERβ 
in PCa is still ill-defined. The cholesterol oxidized metabolite 27-
hydroxycholesterol (27-OHC) has been found to bind to ERs and act as a 
selective ER modulator (SERM). Increased 27-OHC levels are found in 
individuals with hypercholesterolemia, a condition that is suggested to be a risk 
factor for PCa. In the present study, we determined the extent to which 27-OHC 
causes deleterious effects in non-tumorigenic RWPE-1 cells, the low tumorigenic 
LNCaP cells, and highly tumorigenic PC3 prostate cancer cells. We found that 
incubation of LNCaP and PC3 cells with 27-OHC significantly increased cell 
proliferation. We also demonstrate that the ER inhibitor fulvestrant significantly 
reduced 27-OH-induced cell proliferation, indicating the involvement of ERs in
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cell proliferation. Interestingly, ERβ levels, and to a lesser extent ERα, were 
significantly increased following incubation of PCa cells with 27-OHC. 
Furthermore, 27-OHC induced cell proliferation is attenuated in the presence of 
the ERβ specific inhibitor, PHTPP. Altogether, our results show for the first time 
that 27-OHC, through ER activation, triggers deleterious effect in prostate cancer 
cell lines. We propose that dysregulated levels of 27-OHC may trigger or 
exacerbate prostate cancer via acting on ERβ.  
Introduction 
Prostate cancer (PCa) is the second leading cause of death among men 
in the United States (Ferlay et al. 2010). The causes for PCa appear to be 
multifactorial, however it is well established that the incidence of PCa increases 
with age (Ferlay et al. 2010; Zhou et al. 2016). Several risk factors are 
associated with PCa including aging (Zhou et al. 2016), obesity (Gann 2002), 
hormonal imbalance (Gann 2002), oxidative stress (Gann 2002; Bostwick et al. 
2004) and hypercholesterolemia (Magura et al. 2008; Moon et al. 2015).  
ER signaling has been implicated in PCa; the isoform ERβ, and to a lesser 
extent ERα, is expressed in prostate epithelial and stromal cells (Bonkhoff et al. 
1999; Hartman et al. 2012). ERα is considered pro-proliferative (Chakravarty et 
al. 2014) and ERβ anti-proliferative in the context of PCa (Weihua et al. 2002; 
Imamov et al. 2004; McPherson et al. 2008). However ERβ agonists have not 
shown clinical promise to combat PCa (Roehrborn et al. 2015) and there is a gap 
in knowledge elucidating the role of ERβ in PCa. 
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27-hydroxycholesterol (27-OHC) is the most abundant cholesterol 
metabolite in the periphery (Fu et al. 2001; Ma et al. 2014 May 1). Also, 27-OHC 
in plasma increases with age, especially in men (Burkard et al. 2007a). Men also 
have higher basal levels of 27-OHC in the plasma than women (Burkard et al. 
2007a). Moreover, while patients with hypercholesterolemia are at risk for 
developing PCa (Magura et al. 2008), they also have increased 27-OHC levels in 
the blood (Hirayama et al. 2009; Nelson et al. 2011; Nelson et al. 2013). 
Understanding the role of 27-OHC in the context of PCa is critical and may reveal 
the underlying mechanisms responsible for PCa tumor initiation and progression. 
27-OHC is a selective estrogen receptor modulator (SERM) that has been 
identified to bind to ER and modulate its activity (Umetani et al. 2007a; Umetani 
and Shaul 2011). 27-OHC levels are higher among those with 
hypercholesterolemia (Hirayama et al. 2009; Nelson et al. 2011; Nelson et al. 
2013) and older men (Burkard et al. 2007b), both of which are at high risk of 
developing PCa. Also, 27-OHC-induced ER activation has been shown to 
promote ER+ breast cancer growth and progression (Cruz, Torres, María 
Eugenia Ramírez, et al. 2010; Nelson et al. 2013; Wu et al. 2013; Raza et al. 
2015). Given that 27-OHC, at high levels, is associated with risk factors for PCa 
(i.e., hypercholesterolemia and aging) and that 27-OHC modulates ER signaling, 
a pathway that plays a role in PCa development and progression, it is essential 
to study the role of 27-OHC in the context of PCa. Further understanding of the 
role of 27-OHC in PCa may innovate alternative therapeutic avenues to those 
that are currently on the market. 
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We have previously shown that 27-OHC stimulates cell proliferation and 
inhibits docetaxel induced apoptosis in non-tumorigenic prostate epithelial cells 
(Raza et al. 2016). In this study, we determined a role for 27-OHC in activation of 
ERs, leading to deleterious effects in PCa cells.  
Methods 
Reagents 
27-OHC was purchased from Santa Cruz Biotechnologies (Dallas, TX), 
docetaxel, 4-[2-Phenyl-5,7-bis(trifluoromethyl) pyrazolo[1,5-a]pyrimidin-3-
yl]phenol (PHTPP) and Fulvestrant from Cayman Chemicals (Ann Arbor, MI) and 
β-estradiol from Sigma-Aldrich (St. Louis, MO). All cell culture reagents, with the 
exception of fetal bovine serum (FBS) (Atlanta Biologicals; Flowery Branch, GA) 
were from Invitrogen (Carlsbad, CA). Human RWPE-1, LNCaP and PC3 cells 
were purchased from ATCC (Manassas, VA).  
Cell Culture  
Non-tumorigenic human prostate epithelial RWPE-1 cells were maintained in 
Keratinocyte serum free medium (Invitrogen; Carlsbad, CA) supplemented with 
0.05mg/ml BPE and 5ng/ml EGF. Metastatic LNCaP cells were maintained in 
RPMI 1640 medium and highly metastatic PC3 cells were maintained in F-12K 
medium. LNCaP and PC3 cells were supplemented with 10% FBS. All cells were 
supplemented with 100U/ml penicillin, 100μg/ml streptomycin 0.25μg/ml 
amphotericin (Sigma; St. Louis, MO) and cultured at 5% CO2 and 37˚C. Stock 
solutions of 27-OHC were prepared in 100% ethanol and stored at -80°C. 27-
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OHC stock solution was dissolved in appropriate volumes of media to prepare 
the working solutions of 1μM, a concentration that we showed to cause 
proliferation in prostate epithelial cells (Raza et al. 2016). Stock solutions of β-
estradiol were dissolved in 100% ethanol and stored at -80°C. Stock solutions 
were diluted to prepare working solutions of 2nM. Stock solutions of PHTPP and 
fulvestrant were also dissolved in 100% ethanol, stored at -20°C, and diluted 
prior to treatment to prepare working solutions of 10μM. Concentrations of 
solvent in treatments were less than 0.1%. Our study was approved by the 
Institutional Biosafety Committee at the University of North Dakota. 
Cell Proliferation Assay 
Proliferation assays were conducted on black 96 well plates using CyQUANT 
Direct Cell Proliferation Assay (Invitrogen; Carlsbad, CA), which quantifies cell 
number using DNA content and membrane integrity. Cells seeded at 50-60% 
confluence were treated and incubated for 48 hours. Cells were then stained as 
per the manufacturer’s protocol and read using Spectra MAX GEMINI EM 
(Molecular Devices; Sunnyvale, CA). 
Metabolic Activity Assay (MTS assay) 
Cell metabolic activity was quantified by measurement of the reduction of MTS to 
formazan product using CellTiter 96® AQueous One Solution Cell Proliferation 
Assay (Promega; Madison, WI) according to the manufacturer’s protocol. The 
assay of the formation of formazan was performed by measuring absorbance 
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change using a microplate reader (Molecular Devices; Sunnyvale, CA) 48 h after 
treatments.  
Western Blot Analysis 
Treated cells were washed with PBS, trypsinized, and centrifuged at 5000 g. The 
pellets were washed with PBS and homogenized in M-PER tissue protein 
extraction reagent (Thermo Scientific; Waltham, MA) supplemented with 
protease and phosphatase inhibitors. Denatured proteins (5 µg) were separated 
in 10% SDS-PAGE gels, transferred to a PVDF membrane (Millipore; Billerica, 
MA) and incubated with antibodies to ERα (1:1000, Santa Cruz; Dallas,TX) and 
ERβ (1:1000, Millipore, Billerica, MA). β-actin was used as a gel loading control. 
The blots were developed with enhanced chemiluminescence (ECL Clarity kit, 
Bio-Rad). Bands were visualized on a polyvinylidene difluoride membrane and 
analyzed by LabWorks 4.5 software on a UVP Bioimaging System. Quantification 
of results was performed by densitometry and the results analyzed as total 
integrated densitometric values (arbitrary units). 
Invasion assay 
Invasion Assays were conducted using QCM 96-well Cell Invasion Assay kit 
(Millipore; Billerica, MA). The various treatments were added to the wells of the 
feeder tray and at least 1x104 cells/well re-suspended in serum free medium 
were added to the invasion chambers. Cells were incubated with treatments for 
24 hours then stained as per manufacturer’s protocol and transferred to a black 
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96 well plate to read fluorescence using Spectra MAX GEMINI EM (Molecular 
Devices; Sunnyvale, CA). 
Real-time Polymerase Chain Reaction (RT-PCR) 
After treatments, cells were lysed according to QuickGene Mini80 protocol and 
kit (Autogen). RNA sample were quantitated by spectrophotometry and 
subsequently, 1µg total RNA was used as template to synthesize cDNA with the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems; Foster City, 
CA). We selected genes involved in pathways related to 27-OHC, including 
cholesterol metabolism (Björkhem 2013), liver X receptor (LXR) (Lehmann et al. 
1997) and sonic hedgehog (Shh) (Javitt 2008) signaling. We also selected genes 
involved in metastasis (Gorlov et al. 2010; Wang et al. 2013; Broustas and 
Lieberman 2014), oxysterol binding (Vesa M. Olkkonen et al. 2012) and tumor 
suppression(Bereczki et al. 2008). The screened genes are included in Table I. 
Primers for all assays were designed using Primer Express 3.0 (Applied 
Biosystems; Foster City, CA). Melting curve analysis was performed to ensure 
single-product amplification for all primer pairs. Real time PCR was performed on 
the ABI 7900HT Fast Real Time PCR System (Applied Biosystems; Foster City, 
CA) using the panel of genes of interest. Data analysis was performed using 
Sequence Detection System software from Applied Biosystems, version 2.4. The 
experimental Ct (cycle threshold) was calibrated against the endogenous control 
products alpha-ACTIN (ACTN1) and Beta-2-Microglobulin (B2M). Samples were 
















Cholesterol Metabolism Nuclear receptor signaling Shh signaling 
CYP27A1 CYP7B1 HMGCR ABCA1 EZH2 FOXA1 GLI1 GLI2 GLI3 
NFKB1 SRD5A2 SREBF1 NR1H2 NR1H3 RXRA PTCH1 PTCH2 SHH 
     RXRB SIRT1 TFF1 SMO    
      TMPRSS2           
Metastasis Oxysterol Binding Tumor Suppression 
CBX1 CBX5 CTGF INSIG2 OSBP   MDM2 TAF3 TNF 
FN1 IGF-1 IGFBP3      TP53    
MTA1 MTA3 SNAI1           
SNAI2 SPARC VEGFA             
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Table 2: Primers used in determining mRNA expression of significantly regulated 
              genes    
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Coverslip seeded cells were rinsed with PBS and fixed in cold acetone, 
blocked with 10% normal goat serum and incubated overnight at 4˚C with human 
anti-ERβ2 monoclonal antibody (Biorad; Hercules, CA). ERβ2 was conjugated to 
Alexa Fluor 488. All coverslips were washed and mounted with Vectashield 
containing DAPI. Slides were visualized using DMI 6000 (Leica Microsystems; 
Buffalo Grove, IL). 
Statistical analysis 
Differences among groups were assessed by unpaired t-test and One-Way 
Analysis of Variance (One-Way ANOVA) followed by Tukey’s post-hoc test. 
Statistical analysis was performed with GraphPad Prism software 4.01. 
Quantitative data for experimental analysis are presented as mean values ± 
S.E.M with unit value assigned to control and the magnitude of differences 
among the samples being expressed relative to the unit value of control.  
Results 
The cholesterol metabolite 27-OHC increases cell proliferation in PCa 
cells 
We have previously shown that 27-OHC stimulates cell proliferation in non-
tumorigenic RWPE-1 cells (Raza et al. 2016). However, the effects of 27-OHC on 
proliferation in PCa cells were not determined. Here we show that 27-OHC 
stimulates cell proliferation in PCa cells, LNCaP and PC3. Upon 27-OHC 
treatment, cell proliferation was increased by ~60% in LNCaP and ~30% in PC3 
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compared to their respective controls (Fig 21a,b). To confirm our results, we 
performed MTS assay which measures mitochondrial activity of the cells. We 
found that 27-OHC also significantly increases metabolic activity of the both cells 







Figure 21: 27-OHC induces cell proliferation in PCa cells. Cell proliferation assay 
in LNCaP (a) and PC3 (b) cells demonstrates a significant increase in 
proliferation in the presence of 27-OHC. MTS assay shows a significant increase 
in cell metabolic activity in the presence of 27-OHC in LNCaP (c) and PC3 (d) 
cells. Cells were treated with 1µM 27-OHC. Readings were recorded 48 hours 
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after treatment with 27-OHC. Data is expressed as Mean ± S.E.M. ***p<0.001 
versus controls.  
27-OHC stimulates cell proliferation via ER 
Since 27-OHC is a ligand of ER (Umetani and Shaul 2011) and that 27-OHC-
induced ER modulation leads to increased cell proliferation in breast cancer cells 
(Cruz, Torres, María E. Ramírez, et al. 2010; Nelson et al. 2013; Wu et al. 2013; 
Raza et al. 2015), we assessed the importance of ERs in 27-OHC-induced cell 
proliferation in PCa cells. We have previously shown that 27-OHC induced cell 
proliferation in non-tumorigenic prostate epithelial cells was ER dependent (Raza 
et al. 2016). Here, we show that the ER specific inhibitor ICI 182,780 (fulvestrant) 
(McKeage et al. 2004) mitigated 27-OHC induced cell proliferation to basal levels 
in LNCaP and PC3 cells (Fig 22. a,b). Also, we found that upon concomitant 
treatment of 27-OHC and estradiol (E2), the natural agonist of ER (Hall et al. 
2001), there was no additive effect in cell proliferation in both cells (Fig 22. a,b). 





Figure 22: 27-OHC stimulates cell proliferation via ER. Cell proliferation assay in 
LNCaP (a) and PC3 (b) cells demonstrates an attenuation of 27-OHC-induced 
cell proliferation with the ER inhibitor ICI 182,780 (Fulvestrant). Cells were 
treated with 1µM 27-OHC, 2nM of E2 and 10µM ICI 182,780. Readings were 
recorded 48 hours after treatment with 27-OHC. Data is expressed as Mean ± 




27-OHC selectively up-regulates ERβ expression  
Given that 27-OHC stimulates cell proliferation in non-tumorigenic (Raza et al. 
2016) as well as PCa cells (Fig. 21a,b) and that 27-OHC is a ligand of both 
isoforms of ER, ERα and ERβ (DuSell et al. 2010; Umetani and Shaul 2011), we 
determined the extent to which 27-OHC regulates ERα and ERβ protein levels. 
We found that 27-OHC had no significant effects on ERα levels, but significantly 
up-regulated ERβ levels in the non-tumorigenic RWPE-1 (Fig. 23a-c) and PCa 
cells (Fig. 23d-i). When compared to vehicle treated, 27-OHC treated cells exhibit 
an increase in ERβ levels by ~250% in RWPE-1 (Fig. 23c), ~100% in LNCaP 
(Fig. 23f), and ~50% in PC3 (Fig. 23i). This data suggests a potential 




Figure 23: 27-OHC upregulates ERβ expression. Representative western blots 
(a) and densitometric analysis showing no significant change in ERα expression 
in RWPE-1 (b) and a significant increase in ERβ expression (c) in RWPE-1 cells. 
Representative western blots (d) and densitometric analysis showing no 
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significant change in ERα expression (e) and a significant increase in ERβ 
expression in LNCaP cells. Representative western blots (g) and densitometric 
analysis showing no significant change in ERα expression (h) and a significant 
increase in ERβ expression in PC3 cells (i). Data is expressed as Mean ± S.E.M. 
*p<0.05 versus controls. 
27-OHC induces cell proliferation via ERβ 
 To determine if 27-OHC-induced cell proliferation is due to ERβ specific 
activation, we utilized an ERβ specific antagonist PHTPP (Compton et al. 2004). 
Upon treatment of the non-tumorigenic and PCa cells with 27-OHC and PHTPP, 
PHTPP attenuated 27-OHC-induced cell proliferation to basal levels in all cells 
(Fig. 24a-c). This data suggests that ERβ activation is essential for 27-OHC-




Figure 24: 27-OHC induces cell proliferation via ERβ. Cell proliferation assay in 
RWPE-1 (a), LNCaP (b) and PC3 (c) cells demonstrates attenuation of 27-OHC-
induced cell proliferation with PHTPP treatment. Cells were treated with 1µM 27-
OHC and 10µM PHTPP. Readings were recorded 48 hours after treatments. 
84 
 
Data is expressed as Mean ± S.E.M. **p<0.01; ***p<0.001 versus controls, 
##p<0.01; ###p<0.001 versus 27-OHC only treatment. 
27-OHC reduces cell invasion in PCa but not in non-tumorigenic cells 
Cell invasion is a key process by which cancerous cells further tumor progression 
and metastasize to distant tissues and organs. Metastatic cells invade healthy 
tissue by penetrating through the extracellular matrix (ECM) of healthy cells 
(Krakhmal et al. 2015). To investigate the effect of 27-OHC on cell invasion, we 
treated cells with 27-OHC and determined the change in cell invasion across the 
ECM. We found that upon 27-OHC treatment, cell invasion did not significantly 
change in the RWPE-1 cells (Fig. 25a) but significantly decreased in LNCaP and 
PC3 cells (Fig. 25b,c). Also, upon PHTPP treatment only, cell invasion significant 
decreased in non-tumorigenic RWPE-1 and LNCaP cells but not in PC3 cells 
(Fig. 25a-c). Interestingly, PHTPP rescued 27-OHC-induced decrease in cell 
invasion of PC3 cells (Fig. 25c). This data suggests that 27-OHC has no effect 




Figure 25: 27-OHC reduces ECM invasion in PCa cells but not in non-
tumorigenic cells. Cell invasion assay demonstrates that while there was no 
change in invasion in RWPE-1 cells  treated with 27-OHC (a),  a significant 
decrease in cell invasion occurred in LNCaP (b) and PC3 (c) cells treated with 
27-OHC. Cells were treated with 1µM 27-OHC and 10µM PHTPP. Readings 
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were recorded 48 hours after treatment with 27-OHC. Data is expressed as 
Mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 versus controls, #p<0.05 versus 
27-OHC only treatment. 
27-OHC differentially regulates gene expression in non-tumorigenic 
and PCa cells. 
We determined the extent to which 27-OHC related gene expression is regulated 
in normal prostate epithelial RWPE-1 cells and PCa cells (Table 3). We found 
that in non-tumorigenic RWPE-1 cells, the expression levels of TFF1 (PS2) and 
TMPRSS2 were significantly upregulated by 27-OHC treatment. In LNCaP cells, 
CTGF, IGFBP-3, INSIG2, NR1H2 and RXRB was significantly upregulated while 
expression of SREBF-1 and TMPRSS2 was significantly down-regulated. In PC3 
cells, expression of CBX1, CBX5, CYP27A1, CTGF, FOXA1, GLI2, GLI3, MDM2, 
MTA3, OSBP, PTCH1, RXRB and SIRT1 was significantly upregulated and only 
SPARC expression was significantly downregulated (Table 3). The sequences 
for primers of the significantly regulated genes are presented in Table 2. This 
data emphasizes the inherent differences in the cells and the potential genes 







Table 3: Significantly regulated genes in fold change 
Genes RWPE-1  LNCaP PC3 
CBX1 0.9956 1.0503 1.2222* 
CBX5 1.1252 1.0153 1.2895** 
CTGF 0.8859 3.5324* 1.4869** 
CYP27A1 0.5065  N/E 1.2263** 
FOXA1 1.1357 1.1356 1.1534** 
GLI2 0.9029 0.8980 1.3012*** 
GLI3 0.9287 0.9672 1.1714* 
IGFBP3 0.9773 2.3619* 1.1511 
INSIG2 0.9938 1.1923* 1.1851 
MDM2 1.0007 1.0855 1.2051* 
MTA3 1.0713 1.1684 1.2135** 
NR1H2 0.9437 1.1690* 1.1723 
OSBP 1.1333 1.1635 1.2088* 
PTCH1 0.9376 1.3609 1.3304* 
RXRB 1.1306 1.2035* 1.2004** 
SREBF1 0.6093 0.6811* 1.1461 
SIRT1 0.9817 1.1805 1.2671* 
SPARC 0.9115 1.0014 0.8155*** 
TFF1 1.8358* 1.3250 1.0190 
TMPRSS2 1.4082* 0.8474* 1.1262 




27-OHC regulates ERβ2 expression and cellular localization  
ERβ is categorized into several isoforms including ERβ1, ERβ2, ERβ4 and ERβ5 
which are expressed in the prostate gland (Christoforou et al. 2014) . ERβ1 is the 
only functional isoform with a ligand binding domain while the activity of the other 
isoforms may depend on ERβ1 expression and isoform ratios (Christoforou et al. 
2014). The ERβ1 isoform is the most studied isoform which is known to have a 
protective role in prostate cancer while ERβ2 is considered deleterious (M. Chen 
et al. 2009; Nelson et al. 2014) and  known to correlate with poor prognosis 
(Leung et al. 2010). To test whether 27-OHC regulates ERβ2 expression in 
prostate cells, we treated cells with 27-OHC and stained for ERβ2. We found that 
while ERβ2 is expressed in a punctated fashion in the nucleus and the cytoplasm 
in RWPE-1 cells, 27-OHC appeared to increase overall ERβ2 expression (Fig.  
26a). In LNCaP cells, we saw no changes in ERβ2 staining intensity (Fig. 26b.) 
and in PC3 cells we found that 27-OHC appeared to have no overall effect on 
ERβ2 expression (Fig. 26c), however interestingly, stained ERβ2 punctates in 
the nucleus decreased when treated with 27-OHC. This data suggests that 27-
OHC alters the ERβ2 expression and cellular localization depending on the 












Figure 26: 27-OHC differentially regulates ERβ2. Representative fluorescence 
microscopy images of prostate cells depicting ERβ2 (green) expression & 
localization and the nucleus (blue). (a) RWPE-1 cells treated with 27-OHC 
showed increased intensity of ERβ2. (b) LNCaP cells treated with 27-OHC 
depicted no change in ERβ2 staining intensity and (c) PC3 cells treated with 27-
OHC demonstrated no change in overall ERβ2 staining intensity, but a decrease 
in nuclear ERβ2. All cells were treated with1 µM 27-OHC for 24 hr. Bar, 50µm.  
Discussion 
This study investigated the role of 27-OHC in PCa cell models. We 
demonstrate that 27-OHC induces cell proliferation in PCa cells through ER. We 
further show that 27-OHC regulates ERβ expression over ERα. Moreover, we 
demonstrate that 27-OHC-induced cell proliferation is dependent on ERβ 
activation. We also show that 27-OHC reduces ECM cell invasion in PCa cells 
but not in non-tumorigenic cells. Additionally, we found that several genes related 
to oxysterol biology were differentially expressed following 27-OHC treatment in 
non-tumorigenic and PCa cells. Thus, our data show for the first time a potential 
link between 27-OHC and PCa pathogenesis by demonstrating the deleterious 
effect of 27-OHC in PCa cellular models. 
Previously, we have reported that 27-OHC stimulates cell proliferation in 
non-tumorigenic prostate epithelial cells (Raza et al. 2016). Here, we 
demonstrate the effect of 27-OHC in PCa cells. Given that cell proliferation is 
associated with tumor growth, we measured cell proliferation upon 27-OHC 
treatment. We found that 27-OHC significantly increases cell proliferation in 
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tumorigenic LNCaP and PC3 cells. Interestingly, the magnitude of 27-OHC-
induced cell proliferation in LNCaP is higher than PC3. Also, the magnitude of 
27-OHC-induced cell proliferation is higher in RWPE-1 than in LNCaP and PC3.  
The three epithelial cell lines have different morphologies, androgen receptor 
(AR) status, and depict different stages of PCa pathology. RWPE-1 are non-
tumorigenic (Bello et al. 1997), LNCaP are androgen sensitive and with low 
tumorigenicity (Sato et al. 1997), and PC3 are androgen insensitive and highly 
tumorigenic (Kaighn et al. 1979). Taking tumorigenicity of the cells into account, it 
appears that 27-OHC increases cell proliferation to a greater magnitude in 
prostate cells with low or non-tumorigenic phenotypes versus highly tumorigenic 
phenotype. This may suggest the potential role of 27-OHC in early stages of 
PCa. Further studies are warranted to study the role of 27-OHC in forming PCa 
tumors.  
The role of estrogens and estrogen receptors in the context of PCa is 
currently being explored. Recently, estrogens have been associated with the 
development and progression of PCa (Nelles et al. 2011). Moreover, the 
discovery of 27-OHC as a SERM (Umetani and Shaul 2011) adds another 
dimension to the growing phenomena of estrogenic actions as well as cholesterol 
metabolism role in PCas. Our previous (Raza et al. 2016) and current data 
strongly suggest that 27-OHC-induced cell proliferation in non-tumorigenic 
prostate cells and in PCa cells is ER dependent. When cells were treated 
concomitantly with 27-OHC and the ER inhibitor fulvestrant, proliferation was 
substantially attenuated. Given that 27-OHC is known to bind and activate ER 
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(Umetani and Shaul 2011; Wu et al. 2013), our results  suggest that activation of 
ER is required to ensue 27-OHC-induced cell proliferation in PCa cells. This 
observation suggests a potential link between 27-OHC, ER and PCa.  
It is worth noting that 27-OHC can act as an ER agonist or ER antagonist 
depending on the target tissue. For example, 27-OHC activates ER in breast 
tissue (Cruz, Torres, María E. Ramírez, et al. 2010; Nelson et al. 2013; Wu et al. 
2013) and inhibits the receptor in the vasculature (Umetani et al. 2007b).  We 
propose an additional novel concept that 27-OHC activates ER signaling in 
prostate cells and may thus play a pivotal role in PCa development and 
progression. 
Furthermore, we demonstrate that 27-OHC-induced cell proliferation in 
non-tumorigenic and PCa cells is ERβ dependent. When cells are treated with 
the ERβ specific inhibitor PHTPP, 27-OHC-induced cell proliferation is 
attenuated, suggesting the 27-OHC-induced ERβ activation as the underlying 
factor leading to cell proliferation.  
Our results demonstrate that 27-OHC reduces cell invasion in PCa cells 
but not in non-tumorigenic cells. The finding that 27-OHC increases cell 
proliferation but reduces cell invasion is unexpected, however it is in accordance 
with the current environment of diagnosed PCa in which over 90% of PCa 
diagnosed are reported to be localized PCas[51,52]. Additionally, it is important 
to note that cell invasion and proliferation are two different parameters in cancer.  
Moreover, androgen deprivation therapy(ADT) for patients with localized PCa 
does not improve survival or delay the use of secondary cancer therapy[53], 
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suggesting a potential role of 27-OHC-induced estrogenic signaling in localized 
PCa. 
Our study measured expressions of genes regulated by 27-OHC in non-
tumorigenic cells and PCa cells. In non-tumorigenic RWPE-1 cells, we found that 
27-OHC treatment upregulated TFF1 (ps2) and TMPRSS2, downstream targets 
of ER (Shao et al.) and AR (Lucas et al. 2008), respectively. The upregulation of 
these target genes by 27-OHC demonstrates that this oxysterol activates both 
ER and AR target genes. This corroborates our earlier report that AR and ER are 
necessary to induce cell proliferation in 27-OHC-treated  RWPE-1 cells (Raza et 
al. 2016). This observation also substantiates the idea that ER and AR activation 
simultaneously play a significant role in PCa tumor initiation. For instance, when 
Noble rats are concomitantly treated with estradiol and testosterone almost all 
rats develop PCa tumors, while only 40% of them develop PCa when treated with 
testosterone alone (Bosland et al. 1995; Bosland 2005).  
Unlike in RWPE-1 cells, we did not find upregulation of ps2 and 
TMPRSS2 genes by 27-OHC in PCa cells. This may be attributed to the fact that 
LNCaP has a mutated AR (Veldscholte et al. 1992) and that PC3 does not 
express AR (Tai et al. 2011). In PCa cells, we found that the connective tissue 
growth actor (CTGF), which plays a vital role in tumorigenesis and wound healing 
processes (Jacobson and Cunningham 2012) is upregulated by 27-OHC. Also, 
specific to LNCaP, we found a significant upregulation of insulin-like growth 
factor binding protein-3 (IGFBP-3) which has been implicated in PCa tumors. 
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IGFBP-3 is an anti-angiogenic and anti-metastatic protein that is upregulated and 
localized in the nucleus of PCa tumor cells (Seligson et al. 2013). 
Moreover, our results demonstrate that ERβ2 can be regulated by 27-
OHC. In RWPE-1, the cells which obtained the most increase in cell proliferation 
upon 27-OHC treatment, ERβ2 expression increased. Surprisingly while no 
change was observed in LNCaP, PC3 demonstrated a reduction in nuclear ERβ2 
expression, which corresponds to the decreased cell invasion upon 27-OHC 
treatment (Fig 5c). This finding corroborates with the observation that nuclear 
ERβ2 abundance is associated with poor PCa prognosis and increased cell 
invasion(Leung et al. 2010).  
Given the following observations; 27-OHC induced AR transactivation and 
increased cell proliferation in an AR dependent manner in RWPE-1 cells & 27-
OHC does not directly bind to AR (Raza et al. 2016), RWPE-1 is the only cell line 
in this study with a wild type AR (Bello et al. 1997) and it is also the only cell line 
to show an increase in ERβ2 expression upon 27-OHC treatment. Furthermore, 
27-OHC augmented cell proliferation at a greater magnitude in non-tumorigenic 
(RWPE-1) compared to low tumorigenic (LNCaP) and highly tumorigenic PCa 
cells (PC3). Taken together, we hypothesize that 27-OHC may bind and activate 
ERβ inducing downstream AR-ERβ2 crosstalk signaling events leading to 
increased cell proliferation which may result into early stages of PCa. Further 
studies are warranted to test this hypothesis and determine the relationship 




Although there are variations between the both the PCa cells due to their 
difference in phenotypes, they have notable similarities. Both having mutated 
ARs, LNCaP having a mutated AR for increased androgen sensitivity and PC3 
having the mutated AR for decreased androgen sensitivity, hence each cell line 
depicts a different stage of PCa. Also, 27-OHC increased proliferation, 
decreased cell invasion and increased expression of CTGF in both cell lines, 
CTGF is known to play anti-metastatic roles(Chang et al. 2004; Lin et al. 2005). 
These results establish a rationale and prelude to the potential role of 27-OHC in 
promoting tumor growth in localized prostate cancers. 
Altogether, our results demonstrate that 27-OHC induces an increase in 
cell proliferation in PCa cells. We also show for the first time that 27-OHC-
induced cell proliferation is dependent on ER activation, specifically ERβ, in non-
tumorigenic and PCa cells. Our study brings new insights into the potential role of 
27-OHC-evoked effects on ERs in PCa development and progression. Further 
studies delineating underlying mechanisms involved in 27-OHC induced ER-AR 
crosstalk in the context of PCa are warranted and may reveal novel therapeutic 








CONCLUDING REMARKS AND FUTURE DIRECTIONS 
27-OHC and Breast Cancer   
We have demonstrated a novel cellular mechanism of action of 27-OHC 
which is downstream of ER and contributes to proliferation of ER+ breast cancer 
cells. We have shown for the first time that 27-OHC induces an increase in cell 
proliferation in ER+ MCF7 cells via the p53-MDM2 axis (Raza et al. 2015). 
Further in vivo studies are required to corroborate and apply these findings in a 
more clinical model such as breast cancer mouse models. Moreover, while this 
study establishes the importance of 27-OHC mediated ER activation in ER+ 
breast cancer and identifies the p53-MDM2 axis as a potential culprit, many 
pieces of this puzzle are missing. For instance, what are the covalent 
modifications of p53 and MDM2 that contribute to 27-OHC induced p53 inactivity 
or degradation leading to ER+ breast cancer progression? Given that 27-OHC is 
an abundant oxysterol in the circulation, do the oxysterol transport proteins play a 
role in stimulating ER downstream events leading to ER+ breast cancer 
progression? These questions only address part of the missing pieces that are 




Another confounding factor to consider and further investigate is that 27-
OHC is also a ligand for LXR. However, the role of LXR in the etio-pathogenesis 
of breast cancer is poorly understood. Nelson et.al showed that in mice with 
elevated plasma levels of 27-OHC, there is an increase in metastatic lesions and 
epithelial to mesenchymal (EMT) markers (Nelson et al. 2013). Additionally, LXR 
activation via LXR agonist GW3965 also increased metastasis and EMT markers 
(Nelson et al. 2013). However, the question whether 27-OHC induced breast 
cancer metastasis was LXR dependent remains unanswered, since the effect of 
27-OHC on breast cancer metastasis in LXR depleted conditions was not tested. 
It is important to note that while 27-OHC is a ligand of both ERs and LXRs, 27-
OHC is a much more efficacious ligand of ERs when compared to LXRs. 27-
OHC at 1µM binds to ERβ with 90% efficacy and ERα with 50% efficacy (DuSell 
et al. 2008; Umetani and Shaul 2011) while 27-OHC gives a maximum of ~25-
30% efficacy when bound to LXRs at 10µM (Fu et al. 2001; Spencer et al. 2001). 
Notably, intracellular levels of 27-OHC in macrophages can be as high as ~40 
µM (Fu et al. 2001). Thus, due to 27-OHC induced concentration dependent 
activation of ER and LXR, it is important to quantify 27-OHC levels and delineate 
downstream ER-specific and LXR-specific signaling mechanisms in the presence 
of 27-OHC in ER+ breast cancers.  
 Moreover, our experiments used exogenous 27-OHC to induce ER 
activation leading to cell proliferation, however the endogenous availability of 27-
OHC may be sufficient to stimulate cell proliferation and ER+ breast cancer 
growth. Interestingly, Wu et al. (2013) showed that among ER+ breast cancer 
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tissues analyzed, the 27-OHC metabolizing enzyme, CYP7B1 is downregulated 
~50% when compared to normal breast tissue, indicating that the loss of 
localized 27-OHC metabolism may play a significant role in ER+ breast cancer 
tumor growth. Fascinatingly, upon knocking down CYP7B1 in the ER+ breast 
cancer cell line MCF7, without the addition of exogenous 27-OHC, cell 
proliferation increased by a staggering 78% (Wu et al. 2013). These results 
reiterate the deleterious role of tumor localized 27-OHC and perhaps the 
potential therapeutic significance of upregulating CYP7B1 in ER+ breast cancer 
tumors. 
 It is important to note that the widely expressed steroid hydroxylase, 
CYP7B1 not only metabolizes 27-OHC, but also catabolizes a number of other 
steroids such as dehydroepiandrosterone (DHEA), 5-androstene-3β,17β-diol 
(Aene-diol), 5α-androstane-3β,17β-diol (3β-Adiol) and 5α-androstane-3α,17β-diol 
(Lundqvist and Norlin 2012). The implications of these CYP7B1 related steroids 
in the context of ER+ breast cancer are also poorly understood. 
 Moreover, while we now know that 27-OHC exacerbates ER+ breast 
cancer progression, the cellular mechanism of action of 27-OHC is yet to be 
determined. The downstream cascade of events following 27-OHC induced ER 
activation that evokes ER+ breast cancer growth is poorly comprehended. A few 
of the signaling mechanisms involved in 27-OHC induced ER+ breast cancer 
growth are GDNF-RET signaling (Wu et al. 2013) and p53-MDM2 axis (Raza et 
al. 2015). Additionally, estradiol treated breast cancer cells regulated ~9600 
genes while 27-OHC regulated ~2300 genes. Although a significant fraction of 
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genes regulated by estradiol and 27-OHC were the same, almost one third of 
genes regulated by 27-OHC treatment were not regulated by estradiol treatment 
(Nelson et al. 2013). This suggests the importance of studying 27-OHC- specific 
regulating mechanisms which may enhance our knowledge about ER+ breast 
cancer progression. 
27-OHC and Prostate Cancer   
To the best of our knowledge, we are the first to report the deleterious role 
of 27-OHC in the prostate. We have shown that 27-OHC increases cell 
proliferation of non-tumorigenic prostate epithelial cells (RWPE-1) in an ER and 
AR dependent manner. Given the fact that there is no evidence to suggest that 
27-OHC directly binds and activates AR (Raza et al. 2016), this suggests a 
potential crosstalk between ER and AR in the presence of 27-OHC in the 
prostate. We have also shown that 27-OHC induces resistance to docetaxel 
induced apoptosis (Raza et al. 2016). We have also determined, for the first time, 
that 27-OHC induces cell proliferation in PCa cells in an ERβ dependent manner 
[unpublished-under peer review]. These findings warrant further experiments 
involving in vivo models testing the role of 27-OHC in PCa. Given the observation 
that 27-OHC increases cell proliferation in non-tumorigenic prostate epithelial 
cells, pending further experiments, it spotlights the tumorigenic potential of 27-




In addition to the aforementioned limitations, these studies address and 
focus on only one functional component of PCa, in this case, cell proliferation. 
Hyperplasia is one of the beginning stages of PCa and is sustained along with 
the progression of the disease until metastasis occurs. Other functional metrics 
of prostate cancer growth such as metastasis and tumor growth have not been 
fully investigated due to the lack of in vivo resources and experimental models. 
Given the fact that our experiments connecting 27-OHC and PCa were the first to 
be reported, there is a lack of clinically relevant information that would aid our 
research. For instance, currently there is no information available on how much 
27-OHC is found in normal versus PCa tissues. While we do know that 27-OHC 
levels increase with age, whether this increase also occurs in the prostate is yet 
to be determined.   
 In addition to knowing the availability of 27-OHC in the prostate, 
understanding the role of 27-OHC, ER and AR collectively in the context of PCa 
may delineate novel mechanisms involved in PCa. This knowledge may provide 
insights into the design of innovative and more effective therapeutic targets 




 Figure 27: Schematic diagram of the role of 27-OHC in hormonal cancers. 
Cholesterol is converted to 27-hydroxycholesterol by CYP27A1 which 
exacerbates breast cancer proliferation and metastasis by either GDNF-RET 
signaling and/or p53-MDM2 axis. 27-hydroxycholesterol also augments prostate 
cancer proliferation and potentially metastasis through ER-AR crosstalk 






The discovery that 27-OHC is an endogenous SERM has generated 
multiple avenues of medical research especially in the realm of endocrine related 
cancers. However, currently we do not fully comprehend the downstream 
signaling cascades involved in 27-OHC induced ER activation in endocrine 
related cancers. Furthermore, there is a dearth of information on genome-wide 
binding sites of ERs upon 27-OHC induced activation compared to estradiol 
mediated ER activation. Given the complexity of nuclear receptor biology and the 
tissue dependent promiscuous ligand binding activity of 27-OHC to ER and LXR, 
a clearer understanding on how 27-OHC transports and activates receptors in 
different tissues at various concentrations is warranted. Also, the crosstalk 
signaling, if any, between ER and other nuclear receptors, including AR and 
LXR, is yet to be elucidated in the context of hormonal cancers.  
Additionally, further studies are warranted to investigate whether 27-OHC 
binds to the membrane bound ER, G-protein coupled estrogen receptor, GPER 
(GPR30). GPER plays a significant role in propagating the non-genomic pathway 
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of ERs and contributes to cancer progression and metastasis (Arias-Pulido et al. 
2010; Scaling et al. 2014).  
Understanding the mechanisms involved in 27-OHC induced ER activation 
endocrine related cancers can aide us in identifying novel therapeutic targets that 
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